William John Gradishar
#113,732
Most Influential Person Now
William John Gradishar's AcademicInfluence.com Rankings
William John Gradisharphilosophy Degrees
Philosophy
#4855
World Rank
#7516
Historical Rank
Logic
#2234
World Rank
#3181
Historical Rank
Download Badge
Philosophy
William John Gradishar's Degrees
- Doctorate Medicine University of Illinois College of Medicine
Why Is William John Gradishar Influential?
(Suggest an Edit or Addition)William John Gradishar's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. (2005) (1752)
- Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741. (2003) (1462)
- Reduction by Granulocyte Colony-Stimulating Factor of Fever and Neutropenia Induced by Chemotherapy in Patients with Small-Cell Lung Cancer (1991) (1086)
- Breast Cancer, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology. (2020) (615)
- Albumin-bound paclitaxel: a next-generation taxane (2006) (553)
- American Society of Clinical Oncology 2008 clinical practice guideline update: use of chemotherapy and radiation therapy protectants. (2009) (502)
- Breast cancer. Clinical practice guidelines in oncology. (2009) (498)
- Breast Cancer, Version 4.2017, NCCN Clinical Practice Guidelines in Oncology. (2018) (426)
- NCCN Guidelines Insights: Breast Cancer, Version 1.2017. (2017) (344)
- American Society of Clinical Oncology clinical practice guidelines for the use of chemotherapy and radiotherapy protectants. (1999) (344)
- Invasive breast cancer version 1.2016 (2016) (307)
- Enzalutamide for the Treatment of Androgen Receptor-Expressing Triple-Negative Breast Cancer. (2018) (297)
- NCCN Guidelines Insights Breast Cancer, Version 1.2016. (2015) (281)
- Significantly longer progression-free survival with nab-paclitaxel compared with docetaxel as first-line therapy for metastatic breast cancer. (2009) (276)
- Burnout and career satisfaction among US oncologists. (2014) (271)
- Recommendations for prioritization, treatment, and triage of breast cancer patients during the COVID-19 pandemic. the COVID-19 pandemic breast cancer consortium (2020) (270)
- Double-blind, randomized placebo controlled trial of fulvestrant compared with exemestane after prior nonsteroidal aromatase inhibitor therapy in postmenopausal women with hormone receptor-positive, advanced breast cancer: results from EFECT. (2008) (261)
- Targeting the PI3K/AKT/mTOR pathway in triple-negative breast cancer: a review (2018) (258)
- Randomized phase III trial of marimastat versus placebo in patients with metastatic breast cancer who have responding or stable disease after first-line chemotherapy: Eastern Cooperative Oncology Group trial E2196. (2004) (238)
- Neratinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in HER2-Positive Metastatic Breast Cancer Previously Treated With ≥ 2 HER2-Directed Regimens: Phase III NALA Trial (2020) (236)
- HER2 testing in breast cancer: NCCN Task Force report and recommendations. (2006) (205)
- Breast cancer, version 3.2013: featured updates to the NCCN guidelines. (2015) (204)
- NCCN Guidelines Updates: Breast Cancer. (2016) (198)
- Breast Cancer, Version 3.2013 (2013) (193)
- Improved effectiveness of nanoparticle albumin-bound (nab) paclitaxel versus polysorbate-based docetaxel in multiple xenografts as a function of HER2 and SPARC status (2008) (191)
- Breast cancer version 3.2014. (2014) (180)
- Conventional adjuvant chemotherapy with or without high-dose chemotherapy and autologous stem-cell transplantation in high-risk breast cancer. (2003) (180)
- Invasive Breast Cancer Version 1.2016, NCCN Clinical Practice Guidelines in Oncology. (2016) (176)
- Customizing local and systemic therapies for women with early breast cancer: the St. Gallen International Consensus Guidelines for treatment of early breast cancer 2021 (2021) (175)
- The NCCN. Invasive breast cancer: Clinical practice guidelines in oncology™ (2007) (165)
- Breast cancer version 2.2015: Clinical practice guidelines in oncology (2015) (165)
- NCCN Guidelines Insights: Breast Cancer, Version 3.2018. (2019) (154)
- Breast Cancer Version 2.2015. (2015) (149)
- Veliparib with temozolomide or carboplatin/paclitaxel versus placebo with carboplatin/paclitaxel in patients with BRCA1/2 locally recurrent/metastatic breast cancer: randomized phase II study (2018) (149)
- NCCN Task Force Report: Adjuvant Therapy for Breast Cancer. (2006) (147)
- Efficacy of Margetuximab vs Trastuzumab in Patients With Pretreated ERBB2-Positive Advanced Breast Cancer (2021) (140)
- Satisfaction with work-life balance and the career and retirement plans of US oncologists. (2014) (139)
- Invasive breast cancer. (2011) (133)
- NCCN Practice Guidelines for Breast Cancer. (2000) (129)
- Clinical potential of new antiestrogens. (1997) (128)
- Adjuvant lapatinib for women with early-stage HER2-positive breast cancer: a randomised, controlled, phase 3 trial. (2013) (127)
- Continued Treatment Effect of Zoledronic Acid Dosing Every 12 vs 4 Weeks in Women With Breast Cancer Metastatic to Bone: The OPTIMIZE-2 Randomized Clinical Trial (2017) (122)
- Surgical resection of the primary tumor, chest wall control, and survival in women with metastatic breast cancer (2008) (121)
- Metastatic breast cancer, version 1.2012: featured updates to the NCCN guidelines. (2012) (120)
- New Molecular Classifications of Breast Cancer (2009) (118)
- Phase II trial of nab-paclitaxel compared with docetaxel as first-line chemotherapy in patients with metastatic breast cancer: final analysis of overall survival. (2012) (113)
- NCCN Guidelines® Insights: Breast Cancer, Version 4.2021. (2021) (111)
- Targeting Epidermal Growth Factor Receptor in triple negative breast cancer: New discoveries and practical insights for drug development. (2017) (109)
- Breast Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology. (2022) (106)
- Cell-Free DNA and Circulating Tumor Cells: Comprehensive Liquid Biopsy Analysis in Advanced Breast Cancer (2017) (105)
- 90Y radioembolization of metastatic breast cancer to the liver: toxicity, imaging response, survival. (2007) (99)
- Concordance of Genomic Alterations by Next-Generation Sequencing in Tumor Tissue versus Circulating Tumor DNA in Breast Cancer (2017) (97)
- Review: 5-Fluorouracil cardiotoxicity: A critical review (1990) (97)
- Bisphosphonates and Osteonecrosis of the Jaw (2007) (95)
- Evidence-Based Use of Neoadjuvant Taxane in Operable and Inoperable Breast Cancer (2004) (95)
- Changing Treatment Paradigms in Metastatic Breast Cancer: Lessons Learned. (2015) (94)
- Neratinib + capecitabine versus lapatinib + capecitabine in patients with HER2+ metastatic breast cancer previously treated with ≥ 2 HER2-directed regimens: Findings from the multinational, randomized, phase III NALA trial. (2019) (92)
- Capecitabine plus paclitaxel as front-line combination therapy for metastatic breast cancer: a multicenter phase II study. (2004) (91)
- Clinical trials of antiangiogenic agents (1997) (88)
- Randomized Trial of Letrozole Following Tamoxifen as Extended Adjuvant Therapy in Receptor-Positive Breast Cancer: Updated Findings From NCIC CTG MA.17 (2006) (88)
- Clinical validity/utility, change in practice patterns, and economic implications of risk stratifiers to predict outcomes for early-stage breast cancer: a systematic review. (2012) (84)
- Phase I study of alpelisib (BYL-719) and trastuzumab emtansine (T-DM1) in HER2-positive metastatic breast cancer (MBC) after trastuzumab and taxane therapy (2018) (84)
- Phase III, Randomized Study of Dual Human Epidermal Growth Factor Receptor 2 (HER2) Blockade With Lapatinib Plus Trastuzumab in Combination With an Aromatase Inhibitor in Postmenopausal Women With HER2-Positive, Hormone Receptor-Positive Metastatic Breast Cancer: ALTERNATIVE. (2017) (82)
- A double-blind, randomised, placebo-controlled, phase 2b study evaluating sorafenib in combination with paclitaxel as a first-line therapy in patients with HER2-negative advanced breast cancer. (2013) (81)
- NCCN Guidelines Update: Breast Cancer. (2016) (74)
- Tamoxifen--what next? (2004) (74)
- Epirubicin versus doxorubicin: which is the anthracycline of choice for the treatment of breast cancer? (2003) (74)
- PAM50 gene signatures and breast cancer prognosis with adjuvant anthracycline- and taxane-based chemotherapy: correlative analysis of C9741 (Alliance) (2016) (73)
- A pilot study of durvalumab and tremelimumab and immunogenomic dynamics in metastatic breast cancer (2018) (72)
- SOPHIA primary analysis: A phase 3 (P3) study of margetuximab (M) + chemotherapy (C) versus trastuzumab (T) + C in patients (pts) with HER2+ metastatic (met) breast cancer (MBC) after prior anti-HER2 therapies (Tx). (2019) (71)
- Taxanes for the Treatment of Metastatic Breast Cancer (2012) (70)
- A Phase II Study of Single Agent Bortezomib in Patients with Metastatic Breast Cancer: A Single Institution Experience (2007) (70)
- Bevacizumab (Bv) in the adjuvant treatment of HER2-negative breast cancer: Final results from Eastern Cooperative Oncology Group E5103. (2014) (68)
- 5-Fluorouracil cardiotoxicity: a critical review. (1990) (67)
- Long-term outcomes in cancer patients who did or did not pursue fertility preservation. (2018) (67)
- Tamoxifen and contralateral breast cancer. (1999) (66)
- Breast cancer risk reduction. (2010) (66)
- Barriers to the use of personalized medicine in breast cancer. (2012) (64)
- Problem solving for breast health care delivery in low and middle resource countries (LMCs): consensus statement from the Breast Health Global Initiative. (2011) (64)
- αB-crystallin is a novel predictor of resistance to neoadjuvant chemotherapy in breast cancer (2008) (63)
- The sequential use of endocrine treatment for advanced breast cancer: where are we? (2012) (63)
- Safety and efficacy of capecitabine (C) plus bevacizumab (B) as first-line in metastatic breast cancer (2007) (61)
- Invasive breast cancer. (2007) (60)
- Yttrium-90 radioembolization stops progression of targeted breast cancer liver metastases after failed chemotherapy. (2014) (59)
- Phase II neoadjuvant clinical trial of carboplatin and eribulin in women with triple negative early-stage breast cancer (NCT01372579) (2015) (59)
- Docetaxel as neoadjuvant chemotherapy in patients with stage III breast cancer. (1997) (57)
- NCCN Clinical Practice Guidelines in Oncology for Breast Cancer Risk Reduction (2010) (57)
- Triple-Negative Breast Cancer: Current Practice and Future Directions. (2017) (55)
- NCCN Task Force Report: breast cancer in the older woman. (2008) (55)
- Response-Guided Neoadjuvant Chemotherapy for Breast Cancer (2013) (55)
- Prediction of chemotherapy benefit by EndoPredict in patients with breast cancer who received adjuvant endocrine therapy plus chemotherapy or endocrine therapy alone (2019) (55)
- Breast Cancer, Version 3.2022 (2022) (52)
- Association of BRCA1 Mutations with Impaired Ovarian Reserve: Connection Between Infertility and Breast/Ovarian Cancer Risk. (2016) (52)
- Update: NCCN practice guidelines for the treatment of breast cancer. National Comprehensive Cancer Network. (1999) (50)
- Body Mass Index, PAM50 Subtype, and Outcomes in Node-Positive Breast Cancer: CALGB 9741 (Alliance). (2015) (50)
- Emerging approaches for treating HER2-positive metastatic breast cancer beyond trastuzumab. (2013) (49)
- A phase II trial of trastuzumab plus weekly ixabepilone and carboplatin in patients with HER2-positive metastatic breast cancer: an Eastern Cooperative Oncology Group Trial (2010) (48)
- Pharmacokinetics and efficacy of pemetrexed in patients with brain or leptomeningeal metastases (2013) (48)
- Clinical and Translational Results of a Phase II, Randomized Trial of an Anti–IGF-1R (Cixutumumab) in Women with Breast Cancer That Progressed on Endocrine Therapy (2015) (48)
- Oncology fellows’ career plans, expectations, and well-being: do fellows know what they are getting into? (2014) (47)
- HER2 therapy--an abundance of riches. (2012) (47)
- Cancer Therapy Associated Bone Loss: Implications for Hip Fractures in Mid-Life Women with Breast Cancer (2011) (45)
- Effects of cancer treatment on the reproductive system. (1988) (44)
- Phase I trial of escalating doses of paclitaxel plus doxorubicin and dexrazoxane in patients with advanced breast cancer. (1999) (44)
- Selective estrogen-receptor modulators in 2001. (2001) (44)
- nab-Paclitaxel for first-line treatment of patients with metastatic breast cancer and poor prognostic factors: a retrospective analysis (2013) (43)
- Double-Blind Phase III Trial of Adjuvant Chemotherapy With and Without Bevacizumab in Patients With Lymph Node-Positive and High-Risk Lymph Node-Negative Breast Cancer (E5103). (2018) (43)
- Weekly nab-paclitaxel is safe and effective in ≥65 years old patients with metastatic breast cancer: a post-hoc analysis. (2011) (42)
- Everolimus Plus Endocrine Therapy for Postmenopausal Women With Estrogen Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer: A Clinical Trial (2018) (41)
- Phase II study of adozelesin in untreated metastatic breast cancer (1998) (40)
- Neoadjuvant docetaxel followed by adjuvant doxorubicin and cyclophosphamide in patients with stage III breast cancer. (2005) (40)
- The future of breast cancer: the role of prognostic factors (2005) (38)
- Efficacy and safety of continued zoledronic acid every 4 weeks versus every 12 weeks in women with bone metastases from breast cancer: Results of the OPTIMIZE-2 trial. (2014) (38)
- Breast cancer risk reduction, version 2.2015 clinical practice guidelines in oncology clinical practice guidelines in oncology (2015) (38)
- Phase II study of pembrolizumab and capecitabine for triple negative and hormone receptor-positive, HER2−negative endocrine-refractory metastatic breast cancer (2020) (38)
- A phase 3 tRial comparing capecitabinE in combination with SorafenIb or pLacebo for treatment of locally advanced or metastatIc HER2-Negative breast CancEr (the RESILIENCE study): study protocol for a randomized controlled trial (2013) (38)
- Primary care issues for the breast cancer survivor. (1997) (37)
- A Double-Blind, Randomized, Placebo-Controlled, Phase 2b Study Evaluating the Efficacy and Safety of Sorafenib (SOR) in Combination with Paclitaxel (PAC) as a First-Line Therapy in Patients (pts) with Locally Recurrent or Metastatic Breast Cancer (BC). (2009) (37)
- The role of targeted therapy and biomarkers in breast cancer treatment (2012) (37)
- Association of a novel circulating tumor DNA next-generating sequencing platform with circulating tumor cells (CTCs) and CTC clusters in metastatic breast cancer (2019) (36)
- Ovarian function following radiation and chemotherapy for cancer. (1989) (36)
- Pituitary adenoma and bilateral male breast cancer: An unusual association (1997) (36)
- Clinical and cytogenetic responses to granulocyte-macrophage colony-stimulating factor in therapy-related myelodysplasia. (1992) (36)
- High-Dose Chemotherapy for Breast Cancer (1996) (35)
- Dasatinib plus Capecitabine for Advanced Breast Cancer: Safety and Efficacy in Phase I Study CA180004 (2013) (35)
- Pilot neoadjuvant trial in HER2 positive breast cancer with combination of nab-paclitaxel and lapatinib (2012) (34)
- A phase II clinical trial of echinomycin in metastatic soft tissue sarcoma (2004) (34)
- NCCN Guidelines® Insights: Breast Cancer, Version 4.2021. (2021) (32)
- Safety Considerations of Adjuvant Therapy in Early Breast Cancer in Postmenopausal Women (2005) (32)
- ERK-regulated αB-Crystallin Induction by Matrix Detachment Inhibits Anoikis and Promotes Lung Metastasis in vivo (2015) (32)
- alphaB-crystallin is a novel predictor of resistance to neoadjuvant chemotherapy in breast cancer. (2008) (32)
- Management of Metastatic HER2-Positive Breast Cancer: Where Are We and Where Do We Go From Here? (2016) (31)
- Adjuvant Anthracyclines in Breast Cancer: What Is Their Role? (2018) (30)
- Abstract GS1-02: Phase 3 SOPHIA study of margetuximab + chemotherapy vs trastuzumab + chemotherapy in patients with HER2+ metastatic breast cancer after prior anti-HER2 therapies: second interim overall survival analysis (2020) (30)
- Landscape of circulating tumour DNA in metastatic breast cancer (2020) (29)
- Final results of a phase II trial of preoperative TAC (docetaxel/doxorubicin/cyclophosphamide) in stage III breast cancer. (2005) (29)
- Randomized comparison of weekly or every-3-week (q3w) nab-paclitaxel compared to q3w docetaxel as first-line therapy in patients (pts) with metastatic breast cancer (MBC) (2007) (29)
- Long-term hazard of recurrence in HER2+ breast cancer patients untreated with anti-HER2 therapy (2015) (28)
- Estrogen Receptor-Positive, Progesterone Receptor-Negative Breast Cancer: Association With Growth Factor Receptor Expression and Tamoxifen Resistance (2006) (28)
- Gene expression in breast cancer (2006) (28)
- RESILIENCE: Phase III Randomized, Double‐Blind Trial Comparing Sorafenib With Capecitabine Versus Placebo With Capecitabine in Locally Advanced or Metastatic HER2‐Negative Breast Cancer (2017) (28)
- Endocrine Therapy in the Current Management of Postmenopausal Estrogen Receptor-Positive Metastatic Breast Cancer. (2017) (28)
- Prognostic role of serum thymidine kinase 1 activity in patients with hormone receptor-positive metastatic breast cancer: Analysis of the randomised phase III Evaluation of Faslodex versus Exemestane Clinical Trial (EFECT). (2019) (27)
- Phase II study of all-trans-retinoic acid and alpha-interferon in patients with advanced non-small cell lung cancer. (1995) (27)
- The National Physicians Cooperative: transforming fertility management in the cancer setting and beyond (2018) (27)
- Phase III, Randomized Study of Dual Human Epidermal Growth Factor Receptor 2 (HER2) Blockade With Lapatinib Plus Trastuzumab in Combination With an Aromatase Inhibitor in Postmenopausal Women With HER2-Positive, Hormone Receptor-Positive Metastatic Breast Cancer: Updated Results of ALTERNATIVE. (2020) (26)
- Role of capecitabine (Xeloda®) in breast cancer (2003) (26)
- NCCN Breast Cancer Practice Guidelines. The National Comprehensive Cancer Network. (1996) (25)
- Vascular events in patients receiving high-dose infusional 5-fluorouracil-based chemotherapy: the University of Chicago experience. (1991) (25)
- The Relationship Between Agentic and Communal Personality Traits and Psychosocial Adjustment to Breast Cancer (2001) (24)
- nab-Paclitaxel weekly or every 3 weeks compared to standard docetaxel as first-line therapy in patients with metastatic breast cancer: an economic analysis of a prospective randomized trial (2010) (24)
- The cost effectiveness of tamoxifen in the prevention of breast cancer. (1999) (23)
- A Pilot Trial of Suramin in Metastatic Breast Cancer to Assess Antiangiogenic Activity in Individual Patients (2000) (23)
- Sorafenib in locally advanced or metastatic breast cancer (2012) (23)
- Care for a Patient With Cancer As a Project: Management of Complex Task Interdependence in Cancer Care Delivery. (2016) (22)
- Understanding the organ tropism of metastatic breast cancer through the combination of liquid biopsy tools. (2020) (22)
- Fulvestrant: expanding the endocrine treatment options for patients with hormone receptor-positive advanced breast cancer. (2008) (22)
- A phase II trial of capecitabine in combination with the farnesyltransferase inhibitor tipifarnib in patients with anthracycline-treated and taxane-resistant metastatic breast cancer: an Eastern Cooperative Oncology Group Study (E1103) (2012) (22)
- Hormonal therapy for breast cancer. An update. (1999) (22)
- Oncologists' Role in Patient Fertility Care: A Call to Action. (2016) (21)
- An overview of clinical trials involving inhibitors of angiogenesis and their mechanism of action (2004) (21)
- The Place for Eribulin in the Treatment of Metastatic Breast Cancer (2011) (21)
- Breast cancer: updates and advances in 2016 (2017) (20)
- A rationale for the reinitiation of adjuvant tamoxifen therapy in women receiving fewer than 5 years of therapy. (2002) (20)
- Developmental therapeutics for inflammatory breast cancer: Biology and translational directions (2016) (20)
- Biomarker testing for breast, lung, and gastroesophageal cancers at NCI designated cancer centers. (2014) (20)
- Developmental therapeutics for patients with breast cancer and central nervous system metastasis: current landscape and future perspectives. (2017) (19)
- Meta-analysis of selected toxicity endpoints of CDK4/6 inhibitors: Palbociclib and ribociclib. (2017) (19)
- Efficacy of Neratinib Plus Capecitabine in the Subgroup of Patients with Central Nervous System Involvement from the NALA Trial (2021) (19)
- Breast Cancer Outcomes After Diagnosis of Hormone‐positive Breast Cancer and Subsequent Pregnancy in the Tamoxifen Era (2017) (19)
- The 2019 San Antonio Breast Cancer Symposium (2020) (19)
- Chemotherapy‐related hemolytic‐uremic syndrome after the treatment of head and neck cancer. A case report (1990) (19)
- Elevated incidence of fractures in women with invasive breast cancer (2016) (19)
- Markov Model and Cost-Effectiveness Analysis of Bevacizumab in HER2-Negative Metastatic Breast Cancer (2014) (19)
- Adjuvant endocrine therapy for early breast cancer: the story so far. (2010) (18)
- A novel small-molecule antagonizes PRMT5-mediated KLF4 methylation for targeted therapy (2019) (18)
- Performance of a novel Next Generation Sequencing circulating tumor DNA (ctDNA) platform for the evaluation of samples from patients with metastatic breast cancer (MBC). (2019) (18)
- Obstructing plasmacytoma of the duodenum: first manifestation of relapsed multiple myeloma. (1988) (18)
- Durvalumab and tremelimumab in metastatic breast cancer (MBC): Immunotherapy and immunopharmacogenomic dynamics. (2017) (18)
- Current state of clinical trials in breast cancer brain metastases. (2019) (18)
- Dasatinib plus capecitabine (Cap) for progressive advanced breast cancer (ABC): Phase I study CA180004. (2016) (18)
- Controversies in the therapy of early stage breast cancer. (2005) (17)
- Randomized Phase II Study of Ramucirumab or Icrucumab in Combination with Capecitabine in Patients with Previously Treated Locally Advanced or Metastatic Breast Cancer. (2017) (17)
- Role of Fcγ receptors in HER2-targeted breast cancer therapy (2022) (17)
- A Phase II trial of cisplatin plus WR‐2721 (amifostine) for metastatic breast carcinoma (2001) (17)
- Association of Tumor-Infiltrating Lymphocytes with Homologous Recombination Deficiency and BRCA1/2 Status in Patients with Early Triple-Negative Breast Cancer: A Pooled Analysis (2019) (17)
- Systematic analysis of early phase clinical studies for patients with breast cancer: Inclusion of patients with brain metastasis. (2017) (16)
- Selective Progesterone Receptor Modulators in Early-Stage Breast Cancer: A Randomized, Placebo-Controlled Phase II Window-of-Opportunity Trial Using Telapristone Acetate (2019) (16)
- Targeted eHealth Intervention to Reduce Breast Cancer Survivors’ Fear of Recurrence: Results from the FoRtitude Randomized Trial (2021) (16)
- Breast Cancer Risk Reduction, Version 2.2015. (2015) (16)
- From the Past to the Present: Insurer Coverage Frameworks for Next-Generation Tumor Sequencing. (2018) (16)
- The Role of Ovarian Suppression in Premenopausal Women With Hormone Receptor-Positive Early-Stage Breast Cancer. (2015) (15)
- Inflammatory breast cancer: the evolution of multimodality treatment strategies. (1996) (15)
- Feasibility and acceptability of intensive longitudinal data collection of activity and patient-reported outcomes during chemotherapy for breast cancer (2019) (15)
- LBA8A PHASE III RANDOMIZED, DOUBLE-BLIND, TRIAL COMPARING SORAFENIB PLUS CAPECITABINE VERSUS PLACEBO PLUS CAPECITABINE IN THE TREATMENT OF LOCALLY ADVANCED OR METASTATIC HER2-NEGATIVE BREAST CANCER (RESILIENCE) (2014) (14)
- Current controversies in breast cancer management. (1999) (14)
- Breast Cancer (2023) (14)
- BOLERO-4: Phase 2 trial of first-line everolimus (EVE) plus letrozole (LET) in estrogen receptor–positive (ER+), human epidermal growth factor receptor 2–negative (HER2−) advanced breast cancer (BC) (2016) (14)
- Landmark trials in endocrine adjuvant therapy for breast carcinoma (2006) (14)
- Phase I study of alpelisib (BYL-719) and T-DM1 in HER2-positive metastatic breast cancer after trastuzumab and taxane therapy. (2017) (14)
- Evaluation of the 12-Gene Molecular Score and the 21-Gene Recurrence Score as Predictors of Response to Neo-adjuvant Chemotherapy in Estrogen Receptor-Positive, HER2-Negative Breast Cancer (2020) (14)
- Molecular mechanisms and future uses of antiestrogens. (1997) (14)
- The global landscape of treatment standards for breast cancer. (2021) (13)
- Abstract P3-07-12: Homologous recombination deficiency (HRD) as a predictive biomarker of response to neoadjuvant platinum-based therapy in patients with triple negative breast cancer (TNBC): A pooled analysis (2016) (13)
- Novel taxane formulations in the treatment of breast cancer: a thought leader discussion and consensus roundtable. (2008) (13)
- Selective estrogen receptor modulators and prevention of invasive breast cancer. (2006) (13)
- Dose-dense (DD) AC followed by paclitaxel is associated with moderate, frequent anemia compared to sequential (S) and/or less DD Treatment: Update by CALGB on Breast Cancer Intergroup Trial C9741 with ECOG, SWOG, & NCCTG (2005) (13)
- Breast cancer risk reduction. (2010) (13)
- BOLERO-4: Multicenter, open-label, phase II study of everolimus plus letrozole as first-line therapy in ER+, HER2- metastatic breast cancer. (2013) (13)
- The Use of Serial Circulating Tumor DNA to Detect Resistance Alterations in Progressive Metastatic Breast Cancer (2020) (13)
- COVID-19 Pandemic Breast Cancer Consortium’s Considerations for Re-entry (2020) (12)
- Breast Cancer Risk Reduction Clinical Practice Guidelines in Oncology. (2007) (12)
- JNCCN HER 2 Testing in Breast Cancer : NCCN Task Force Report and Recommendations (2006) (12)
- Current and future perspectives on fulvestrant. (2005) (12)
- Management of advanced breast cancer with the epothilone B analog, ixabepilone (2009) (12)
- Are Biosimilars the Future of Oncology and Haematology? (2019) (12)
- Advances in Endocrine Therapy for Postmenopausal Metastatic Breast Cancer. (2018) (12)
- A phase II study of the proteasome inhibitor PS-341 in patients (pts) with metastatic breast cancer (MBC). (2004) (12)
- Weekly Paclitaxel in the Adjuvant Treatment of Breast Cancer (2008) (12)
- Breast Cancer Research and Treatment 2001 Reviewers (2004) (12)
- Albumin-bound paclitaxel (ab-pac) versus docetaxel for first-line treatment of metastatic breast cancer (MBC): Final overall survival (OS) analysis of a randomized phase II trial. (2011) (11)
- Longitudinal Dynamics of Circulating Tumor Cells and Circulating Tumor DNA for Treatment Monitoring in Metastatic Breast Cancer (2021) (11)
- Endpoints for Determination of Efficacy of Antiangiogenic Agents in Clinical Trials (1999) (11)
- Developmental therapeutics for patients with breast cancer and central nervous system metastasis: current landscape and future perspectives. (2016) (11)
- Phase III study of lapatinib (L) plus trastuzumab (T) and aromatase inhibitor (AI) vs T+AI vs L+AI in postmenopausal women (PMW) with HER2+, HR+ metastatic breast cancer (MBC): ALTERNATIVE. (2017) (11)
- A pilot study of cabergoline for the treatment of metastatic breast cancer (2017) (11)
- LPTO-02. INTRATHECAL (IT) TRASTUZUMAB (T) FOR THE TREATMENT OF LEPTOMENINGEAL DISEASE (LM) IN PATIENTS (PTS) WITH HUMAN EPIDERMAL RECEPTOR-2 POSITIVE (HER2+) CANCER: A MULTICENTER PHASE 1/2 STUDY (2019) (11)
- A phase II clinical trial of echinomycin in metastatic soft tissue sarcoma. An Illinois Cancer Center Study. (1995) (11)
- Reducing Disparities in Breast Cancer Survival: A Columbia University and Avon Breast Cancer Research and Care Network Symposium* (2002) (11)
- Breast cancer and immunology: biomarker and therapeutic developments (2015) (10)
- Advances in Breast Cancer Management (2000) (10)
- Single-agent topotecan as first-line chemotherapy in women with metastatic breast cancer: final results of eastern cooperative oncology group trial E8193. (2005) (10)
- Treatment challenges for community oncologists treating postmenopausal women with endocrine-resistant, hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer (2016) (10)
- NCCN Guidelines Updates: Breast Cancer. (2019) (10)
- A hospice/palliative medicine rotation for fellows training in hematology-oncology. (2009) (10)
- Predictors and outcomes in breast cancer patients who did or did not pursue fertility preservation (2021) (10)
- Adjuvant systemic therapy of early stage breast cancer (2003) (10)
- Biomarker Analysis of the Phase III NALA Study of Neratinib + Capecitabine versus Lapatinib + Capecitabine in Patients with Previously Treated Metastatic Breast Cancer (2021) (10)
- Analyses of selected safety endpoints in phase 1 and late-phase clinical trials of anti-PD-1 and PD-L1 inhibitors: prediction of immune-related toxicities (2017) (9)
- Breast cancer: noninvasive and special situations. (2010) (9)
- Tucatinib, palbociclib, and letrozole in HR+/HER2+ metastatic breast cancer: Report of phase IB safety cohort. (2019) (9)
- Recent developments: Breast cancer (2002) (9)
- Treatment of metastatic breast cancer. (2014) (9)
- The 21-gene recurrence score in node-positive, hormone receptor-positive, HER2-negative breast cancer: a cautionary tale from an NCDB analysis (2020) (9)
- Letters to the editor: 5-Fluorouracil cardiotoxicity: The risk of rechallenge (1991) (9)
- High-dose chemotherapy and breast cancer. (1999) (9)
- Increased HER2/neu expression in recurrent hormone receptor-positive breast cancer (2010) (9)
- Everolimus (EVE) plus endocrine therapy in patients with estrogen receptor–positive (ER+), human epidermal growth factor receptor 2–negative (HER2−) advanced breast cancer (BC): First- and second-line data from the BOLERO-4 study. (2017) (9)
- S4-7: Results of a Randomized, Double-Blind, Multicenter, Placebo-Controlled Study of Adjuvant Lapatinib in Women with Early-Stage ErbB2-Overexpressing Breast Cancer. (2011) (8)
- Differences Are Important: Breast Cancer Therapy in Different Ethnic Groups (2017) (8)
- CMET-22. INTRATHECAL (IT) TRAZTUZUMAB (T) FOR THE TREATMENT OF LEPTOMENINGEAL METASTASES (LM) IN PATIENTS (PTS) WITH HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2-POSITIVE (HER2+) CANCER: A MULTICENTER PHASE 1/2 STUDY (2018) (8)
- Analyses of selected safety endpoints in phase 1 and late-phase clinical trials of anti-PD-1 and PD-L1 inhibitors: prediction of immune-related toxicities. (2017) (8)
- Adjuvant chemotherapy in patients with invasive lobular carcinoma and use of the 21‐gene recurrence score: A National Cancer Database analysis (2022) (8)
- Issues in Breast Cancer Survivorship: Optimal Care, Bone Health, and Lifestyle Modifications. (2016) (8)
- 265P Study of samuraciclib (CT7001), a first-in-class, oral, selective inhibitor of CDK7, in combination with fulvestrant in patients with advanced hormone receptor positive HER2 negative breast cancer (HR+BC) (2021) (8)
- Randomized comparison of nab-paclitaxel weekly or every 3 weeks compared to docetaxel every 3 weeks as first-line therapy in patients (pts) with metastatic breast cancer (MBC) (2008) (7)
- Daily Physical Activity and Symptom Reporting in Breast Cancer Patients Undergoing Chemotherapy: An Intensive Longitudinal Examination (2020) (7)
- De-escalation of Endocrine Therapy in Early Hormone Receptor-positive Breast Cancer: When Is Local Treatment Enough? (2021) (7)
- To Boost or Not to Boost (2009) (7)
- Cost-effectiveness of nanoparticle albumin-bound (nab) paclitaxel (ABX) vs Cremophor-based paclitaxel (CP) in the treatment of metastatic breast cancer (MBC). (2004) (7)
- Abstract PD8-01: Phase 3 SOPHIA study of margetuximab (M) + chemotherapy (CTX) vs trastuzumab (T) + CTX in patients (pts) with HER2+ metastatic breast cancer (MBC) after prior anti-HER2 therapies: Final overall survival (OS) analysis (2022) (7)
- Clinical roundtable monograph: effective management of quality of life in metastatic breast cancer. (2014) (7)
- Plasma matrix metalloproteinases 7 and 9 in patients with metastatic breast cancer treated with marimastat or placebo: Eastern Cooperative Oncology Group trial E2196. (2006) (7)
- Counterpoint: the argument for combination chemotherapy in the treatment of metastatic breast cancer. (2007) (7)
- SOPHIA: A phase 3, randomized study of margetuximab (M) plus chemotherapy (CTX) vs trastuzumab (T) plus CTX in the treatment of patients with HER2+ metastatic breast cancer (MBC). (2016) (7)
- The 2020 San Antonio Breast Cancer Symposium (2021) (6)
- Primary (neoadjuvant) chemotherapy with docetaxel in breast cancer. (2001) (6)
- Proceedings of the First Global Workshop on Breast Cancer: pathways to the evaluation and clinical development of novel agents for breast cancer. (2010) (6)
- Progress in systemic adjuvant therapy of early-stage breast cancer (2003) (6)
- The Application of Oncotype DX in Early-Stage Lymph-Node-Positive Disease (2014) (6)
- Clinical status of capecitabine in the treatment of breast cancer. (2001) (6)
- Primary chemotherapy regimens and schedules. (1998) (6)
- A Roundtable Discussion of Aromatase Inhibitors as Therapy for Breast Cancer (2003) (6)
- Adjuvant Therapy of Breast Cancer (2005) (6)
- A phase I trial of pegylated liposomal anthracycline and lapatinib (L) combination in the treatment of metastatic breast cancer (MBC): First evaluation of an anthracycline and lapatinib combination in the treatment of MBC (2007) (6)
- Dasatinib Plus Capecitabine for Advanced Breast Cancer: Safety and Efficacy Data from Phase 1 Study CA180-004. (2009) (6)
- Tumor-Infiltrating Lymphocytes in Breast Cancer (2016) (6)
- 1O Neratinib + capecitabine vs lapatinib + capecitabine in HER2+ metastatic breast cancer previously treated with ≥2 HER2-directed regimens: Exploratory biomarker analyses from phase III NALA trial (2020) (6)
- Fulvestrant in the treatment of postmenopausal women with advanced breast cancer (2005) (6)
- Breast Cancer and (2009) (6)
- Recently initiated studies: neoadjuvant treatments in the next century. (1999) (5)
- Male Breast Cancer (2018) (5)
- Clinical roundtable monograph: a multidisciplinary approach to the use of oncotype DX in clinical practice. (2009) (5)
- Optimizing Breast Cancer Management (2018) (5)
- Breast cancer (2002) (5)
- A Phase I/II Study of Intrathecal Trastuzumab in HER-2 Positive Cancer with Leptomeningeal Metastases: Safety, Efficacy, and Cerebrospinal Fluid Pharmacokinetics. (2022) (5)
- U.S. prevalence of endocrine therapy-naïve locally advanced or metastatic breast cancer. (2019) (5)
- Multivariate analysis (MVA) of progression-free survival (PFS) in two phase IIb, multinational, double-blind, randomized, placebo (PL)-controlled trials evaluating sorafenib (SOR) plus standard chemotherapy in patients (pts) with HER2-negative locally advanced or metastatic breast cancer (BC). (2010) (5)
- The Impact on Survival by Adjuvant Chemotherapy and Radiation Therapy in Stage II Non‐Small‐Cell Lung Cancer (1992) (5)
- Adjuvant Therapy of Breast Cancer (1992) (5)
- A pilot study of palbociclib in patients with HER2-positive breast cancer with brain metastasis. (2017) (5)
- Ixabepilone plus Capecitabine for Metastatic Breast Cancer (2010) (5)
- Inhibitors of Tumor Angiogenesis (2011) (5)
- Abstract PD2-04: Baseline circulatingESR1mutation analysis in the randomised phase III EFECT study of fulvestrant versus exemestane in advanced hormone receptor positive breast cancer (2019) (5)
- Abstract P2-10-01: PAM50 gene signature is prognostic for breast cancer patients treated with adjuvant anthracycline and taxane based chemotherapy (2012) (5)
- Choosing between Endocrine Therapy and Chemotherapy – or is there a Role for Combination Therapy? (2002) (5)
- Adjuvant therapy of breast cancer in the elderly: does one size fit all? (2005) (5)
- Design of RESILIENCE: A phase (Ph) III trial comparing capecitabine (CAP) in combination with sorafenib (SOR) or placebo (PL) for treatment (tx) of locally advanced (adv) or metastatic HER2-negative breast cancer (BC). (2011) (5)
- Phase IIb double-blind, randomized, placebo-controlled trials for the efficacy and safety of sorafenib in patients (pts) with metastatic or locally advanced breast cancer (BC): Review of the Trials to Investigate the Effects of Sorafenib in BC (TIES) program. (2009) (5)
- Clinical efficacy and emerging therapeutic utilization of novel taxanes (2008) (4)
- No pain, no gain: a fallacy so far. (2015) (4)
- Predicting Expected Absolute Chemotherapy Treatment Benefit in Women With Early-Stage Breast Cancer Using EndoPredict, an Integrated 12-Gene Clinicomolecular Assay (2019) (4)
- Abstract 1597: Increased circulating tumor cell (CTC) after systemic therapy is associated with younger age in stage III/IV breast cancer patients (2018) (4)
- The 2018 San Antonio Breast Cancer Symposium (2018) (4)
- Advances in endocrine therapy of metastatic breast cancer (2002) (4)
- Racial Disparities in Breast Cancer (2009) (4)
- Settings-based efficacy comparison of trastuzumab biosimilars in breast cancer: A systematic literature review. (2018) (4)
- Timing of genetic testing relative to breast cancer surgery. (2010) (4)
- Overall survival analysis of a randomized phase III trial comparing nab-paclitaxel with solvent-based paclitaxel in patients with metastatic breast cancer previously treated with anthracycline (2008) (4)
- Increased HER2 expression in women with recurrent ER positive breast cancer (2007) (4)
- The 2016 San Antonio Breast Cancer Symposium (2017) (4)
- Identification of early breast cancer patient cohorts who may benefit from lapatinib therapy. (2016) (4)
- What do providers, payers and patients need from comparative effectiveness research on diagnostics? The case of HER2/Neu testing in breast cancer. (2013) (4)
- Social cognitive variables and physical activity during chemotherapy for breast cancer: An intensive longitudinal examination (2021) (4)
- Biological Subtypes of Breast Cancer (2015) (4)
- Circulating tumor cells, circulating tumor DNA, and disease characteristics in young women with metastatic breast cancer (2021) (4)
- BRCA+ test result impact and timing on surgical treatment decisions for patients with breast cancer. (2011) (4)
- Phase II neoadjuvant trial with carboplatin and eribulin mesylate in patients with triple-negative breast cancer. (2012) (4)
- OT3-01-09: Phase 3 Trial Comparing Capecitabine in Combination with SorafenIb or Placebo for Treatment of Locally Advanced or Metastatic HER2−Negative Breast Cancer (RESILIENCE). (2011) (4)
- Diagnostic and treatment considerations when newly diagnosed breast cancer coincides with pregnancy: a case report and review of literature. (2012) (4)
- The evolving role of endocrine therapy for treatment and prevention of breast cancer. (2001) (3)
- Relationship of pathological features and a 21 gene expression assay in younger versus older women with node-negative endocrine receptor-positive breast cancer (2018) (3)
- HER2 and SPARC status in tumors may play an important role in the relative effectiveness of nanoparticle albumin-bound (nab(r)) paclitaxel versus polysorbate-based docetaxel (2008) (3)
- Margetuximab Versus Trastuzumab in Patients With Previously Treated HER2-Positive Advanced Breast Cancer (SOPHIA): Final Overall Survival Results From a Randomized Phase 3 Trial (2022) (3)
- SOPHIA analysis by chemotherapy (Ctx) choice: A phase III (P3) study of margetuximab (M) + Ctx versus trastuzumab (T) + Ctx in patients (pts) with pretreated HER2+ metastatic (met) breast cancer (MBC). (2020) (3)
- Phase I study of alpelisib and T-DM1 in trastuzumab-refractory HER2-positive metastatic breast cancer. (2016) (3)
- A Phase I Trial of a Pegylated Liposomal Anthracycline (DoxilTM) and Lapatinib Combination in the Treatment of Metastatic Breast Cancer: Dose-Escalation Results of an Anthracycline and Lapatinib Combination Trial. (2009) (3)
- Abstract P3-01-19: HER2-positive circulating tumor cells (CTCs) in advanced breast cancer (BC): A feature independent of BC subtype (2019) (3)
- A phase 2 single-arm study to assess clinical activity, efficacy and safety of enzalutamide (ENZA) with trastuzumab in HER2+ AR+ metastatic or locally advanced breast cancer. (2015) (3)
- Advances in endocrine therapy for the treatment and prevention of breast cancer. (2003) (3)
- Nab-Paclitaxel versus Docetaxel for the First-line Treatment of Metastatic Breast Cancer (2013) (3)
- Abstract OT1-02-07: SOPHIA: A phase 3, randomized study of margetuximab plus chemotherapy vs trastuzumab plus chemotherapy in the treatment of patients with HER2+ metastatic breast cancer (2017) (3)
- Clinical Aspects of Breast Cancer (1996) (3)
- A Technology-Based Physical Activity Intervention for Patients With Metastatic Breast Cancer (Fit2ThriveMB): Protocol for a Randomized Controlled Trial (2021) (3)
- Abstract PS9-02: Neratinib + capecitabine sustains health-related quality of life (HRQoL) while improving progression-free survival (PFS) in patients with HER2+ metastatic breast cancer and ≥2 prior HER2-directed regimens (2021) (3)
- Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) Trial After Completion of 5 Years' Adjuvant Treatment for Breast Cancer (2006) (3)
- 5060 POSTER Albumin-bound Paclitaxel (ab-pac) Versus Docetaxel for First-line Treatment of Metastatic Breast Cancer (MBC): Overall Survival (OS) Subset Analyses of a Randomized Phase 2 Trial (2011) (3)
- Pilot Neoadjuvant Trial with Combination of Lapatinib and Nab-Paclitaxel in HER2+ Breast Cancer. (2009) (3)
- Current data and ongoing trials with novel taxane formulations in metastatic breast cancer (2008) (3)
- Capecitabine plus paclitaxel as first- Or second-line therapy: A multicenter phase II study in metastatic breast cancer (2001) (3)
- Abstract PD4-05: Patterns of genomic alterations in ER-positive advanced breast cancer patients treated with CDK4/6 inhibitors (2018) (3)
- Case records of the Massachusetts General Hospital. Case 30-2008. A 47-year-old woman with a mass in the breast and a solitary lesion in the spine. (2008) (3)
- Optimizing Treatment of HER2-Positive Breast Cancer. (2015) (3)
- Adjuvant and neoadjuvant systemic therapies for early-stage breast cancer (2018) (3)
- Use of a best-practice advisory to increase survivorship clinic referrals. (2017) (3)
- Phase II trial of etoposide and doxorubicin in advanced head and neck cancer. (1990) (3)
- 463 A multicenter phase II study of capecitabine plus paclitaxel in metastatic breast cancer: Survival update (2003) (3)
- Clinical value of fulvestrant in breast cancer. (2005) (3)
- The evolving role of endocrine therapy for early stage breast cancer (2005) (3)
- Biomarker testing methods in breast, gastric, and lung cancers: A benchmarking survey of NCI cancer centers. (2013) (2)
- Abstract PD13-09: Impact of neratinib on outcomes in HER2-positive metastatic breast cancer patients with central nervous system disease at baseline: Findings from the phase 3 NALA trial (2021) (2)
- Predicting expected absolute chemotherapy treatment benefit in women with early-stage breast cancer using a 12-gene expression assay. (2018) (2)
- The Unmet Need for Effective Treatment of Triple-Receptor Negative Breast Cancer. (2014) (2)
- The 2013 San Antonio Breast Cancer Symposium (2014) (2)
- Updates in HER2-Positive and Triple-Negative Breast Cancers (2021) (2)
- A phase II study of pembrolizumab and capecitabine for triple-negative (TN) and hormone receptor-positive, HER2-negative endocrine-refractory metastatic breast cancer (MBC). (2019) (2)
- Advances in adjuvant chemotherapy for breast cancer: the role of taxanes. (2003) (2)
- 413 Relationship Between Body Mass Index (BMI) and Outcomes in Node-positive Breast Cancer Patients Receiving Chemotherapy–Results From CALGB/Intergroup 9741 (2012) (2)
- Supportive care of the lung cancer patient (1990) (2)
- Abstract OT1-1-04: ALTERNATIVE: safety and efficacy of lapatinib (L), trastuzumab (T), or both in combination with an aromatase inhibitor (AI) for the treatment of hormone receptor-positive (HR+), human epidermal growth factor receptor 2 positive (HER2+) metastatic breast cancer (2012) (2)
- Dynamic changes of interleukin 2 (IL-2) and circulating tumor cells (CTCs) in patients with advanced breast cancer (BCa) after systemic therapies. (2018) (2)
- Individualizing treatment to optimize survival outcomes in breast cancer. (2013) (2)
- Bevacizumab in the Treatment of Metastatic Breast Cancer (2007) (2)
- Abstract PS10-03: Interim safety and efficacy analysis of phase IB / II clinical trial of tucatinib, palbociclib and letrozole in patients with hormone receptor and HER2-positive metastatic breast cancer (2021) (2)
- The 40th Annual San Antonio Breast Cancer Symposium (2018) (2)
- Barriers to implementing primary HER2 FISH testing. (2011) (2)
- A regional subgroup analysis of a multinational, double-blind, randomized, placebo-controlled, phase IIb study evaluating sorafenib (SOR) with paclitaxel (PAC) in patients (pts) with advanced breast cancer (BC). (2010) (2)
- The role of targeted therapy and biomarkers in breast cancer treatment (2012) (2)
- Efficacy of Nab-paclitaxel in patients with poor prognostic factors or with anthracycline-resistant metastatic breast cancer (MBC) (2008) (2)
- The 2012 San Antonio Breast Cancer Symposium (2013) (2)
- Ductal carcinoma in situ of breast: from molecular etiology to therapeutic management. (2022) (2)
- A phase I study of the oral platinum agent satraplatin (S) in with capecitabine (C) in patients (pts) with advanced solid malignancies (2008) (2)
- Abstract P5-17-01: Bevacizumab (B) in the adjuvant treatment of breast cancer - first toxicity results from Eastern Cooperative Oncology Group trial E5103. (2012) (2)
- Circulating tumour DNA characterisation of invasive lobular carcinoma in patients with metastatic breast cancer (2022) (2)
- Hormonal Therapy for Breast Cancer (2005) (2)
- Abstract P1-12-07: A Retrospective Analysis ofnab-Paclitaxel as First-Line Therapy for Metastatic Breast Cancer Patients With Poor Prognostic Factors (2012) (2)
- Comprar The Breast. Comprehensive Management Of Benign And Malignant Diseases (Print And Online) 5th Ed | William J. Gradishar | 9780323359559 | Elsevier Internacional (2017) (2)
- Innovating Cancer Care Delivery: the Example of the 4R Oncology Model for Colorectal Cancer Patients (2019) (2)
- Tumor Infiltrating Lymphocytes and HER2-Positive Breast Cancer (2017) (2)
- Abstract PS10-12: Integrated safety summary of single agent and combination margetuximab in phase 1, 2, and 3 studies of HER2-positive advanced cancers and metastatic breast cancer (MBC) (2021) (2)
- Adjuvant lapatinib in women with early-stage HER2-positive breast cancer (HER2+ BC): Analysis of the hormone receptor-negative subgroup of the intent-to-treat (ITT) population of the TEACH trial. (2012) (2)
- Evaluation of the Novel 4R Oncology Care Planning Model in Breast Cancer: Impact on Patient Self-Management and Care Delivery in Safety-Net and Non-Safety-Net Centers. (2021) (2)
- Abstract P6-09-09: Evaluation of tumor infiltrating lymphocytes (TILs) and their association with homologous recombination deficiency and BRCA1/2 mutation status in triple-negative breast cancer (TNBC): A pooled analysis (2017) (2)
- Phase I trial of pegylated liposomal doxorubicin and lapatinib in the treatment of metastatic breast cancer (MBC): Final results. (2012) (2)
- Adjuvant Chemotherapy in Older Patients with Breast Cancer (2009) (2)
- Abstract 408: Expression of CCR5 associated with HER2 in circulating tumor cells (CTCs) is a novel biomarker for patients with metastatic breast cancer (MBC) (2019) (2)
- Abstract P6-13-11: Phase I study of alpelisib and T-DM1 in trastuzumab-refractory HER2-positive metastatic breast cancer (2016) (2)
- Abstract P6-11-03: A phase 2 open-label study of lucitanib in patients (pts) with FGF aberrant metastatic breast cancer (MBC) (2017) (2)
- Does the 4R oncology model improve clinicians’ effectiveness in patient-facing planning of complex cancer care? (2022) (2)
- NCCN Guidelines Updates: Management of Patients With HER2-Negative Breast Cancer (2022) (2)
- Results from a pilot of an innovative 4R Cancer Care Delivery Model in early breast cancer: Impact on timing and sequencing of guideline recommended care. (2018) (2)
- The 2015 San Antonio Breast Cancer Symposium (2016) (2)
- Prognosis and Chemotherapy Use in Breast Cancer Patients with Multiple Lymphatic Micrometastases: An NCDB Analysis (2021) (2)
- Introduction Clinical Value of Fulvestrant in Breast Cancer (2005) (1)
- NCCN Breast Cancer Risk Reduction Clinical Practice Guidelines in Oncology (2010) (1)
- Written care plan and patient enablement: Pre-implementation data from the 4R in Oncology Project. (2017) (1)
- Pharmacology and Use of Antiestrogens in Treatment and Chemoprevention of Breast Cancer (1999) (1)
- What are NCI-designated cancer centers using for breast cancer HER2 testing? (2013) (1)
- New Approaches to Endocrine Therapy for Breast Cancer. (2017) (1)
- Medical and Neuro-Oncology (2010) (1)
- Comparison of weekly and every-3-week nab-paclitaxel in elderly patients with metastatic breast cancer (2008) (1)
- Locally Advanced Breast Cancer (2018) (1)
- Abstract P3-07-25: Improved clinical outcomes on enzalutamide observed in patients with PREDICT AR+ triple-negative breast cancer: prognosis or prediction? (2016) (1)
- Positive predictive value of ERBB2 copy number gain by tissue or circulating tumor DNA next-generation sequencing across advanced cancers (2022) (1)
- Abstract P1-02-11: Somatic alterations and PD-L1 positivity in advanced breast cancer (2022) (1)
- Phase II neoadjuvant clinical trial of carboplatin and eribulin in women with triple negative early stage breast cancer (NCT01372579). (2015) (1)
- ER-Positive Breast Cancer Remains a Long-Term Concern (2017) (1)
- Hormonal therapy for primary breast cancer: Scientific rationale and status of clinical research (2005) (1)
- Abstract OT1-03-06: Phase IB/II clinical trial to evaluate safety and efficacy of tucatinib in combination with palbociclib and letrozole in patients with hormone receptor positive and HER2-positive metastatic breast cancer (2018) (1)
- Promoting patient health maintenance with cancer care planning at diagnosis and during treatment: baseline data of the Coleman Supportive Oncology Collaborative (CSOC). (2020) (1)
- Do Genomic Assays Provide the Necessary Confidence to De-escalate Adjuvant Therapy? (2018) (1)
- Results from a pilot of an innovative 4R Cancer Care Delivery Model: Impact on patient self-management. (2018) (1)
- Abstract P5-01-08: Landscape of circulating tumor DNA (ctDNA) in metastatic breast cancer (2020) (1)
- Evidence-driven, patient-specific approaches for optimizing survival prolongation in breast cancer. (2014) (1)
- Are Tumor-Infiltrating Lymphocytes Prognostic in Triple-Negative Breast Cancer? (2019) (1)
- P5-19-13: A Randomized Phase II Trial of First-Line Metastatic Breast Cancer (MBC) Patients: Sub-Set Analysis of Albumin-Bound Paclitaxel (ab-pac) Given Weekly at 150 mg/m2. (2011) (1)
- Supportive care of the lung cancer patients. (1990) (1)
- Abstract 5195: Increased circulating tumor cell (CTC) clusters are associated with significantly higher levels of HER2 expression and metastasis in stage III/IV breast cancer (2018) (1)
- Abstract OT2-2-02: Phase I/II clinical trial on the combination of carboplatin, eribulin and E7449 (2015) (1)
- Brain Metastases in Triple-Negative Breast Cancer (2009) (1)
- Oncology Medical Home to address challenges in breast cancer care delivery. (2011) (1)
- Skeletal issues and bone health in patients with cancer. Introduction. (2009) (1)
- Nab-paclitaxel weekly or q3w compared to docetaxel q3w as first-line therapy in patients with metastatic breast cancer: An economic analysis of a prospective randomized trial. (2009) (1)
- Hormone therapy in postmenopausal women with breast cancer (2005) (1)
- Quality of life in patients with metastatic breast cancer. (2014) (1)
- Ongoing clinical development of lapatinib in HER2-positive (HER2+) metastatic breast cancer (MBC): An innovative approach to recruit patients in clinical studies. (2011) (1)
- Abstract A065: Neoadjuvant phase II trial with eribulin and carboplatin in patients with triple-negative breast cancer (2013) (1)
- The 2011 San Antonio Breast Cancer Symposium (2012) (1)
- Role of serum thymidine kinase-1 (TK1) activity in patients (pts) with hormone receptor positive (HR+) advanced breast cancer (ABC) treated with endocrine therapy (ET) in the EFECT trial. (2018) (1)
- In silico evaluation of the 12-gene molecular score (EndoPredict) and the recurrence score (Oncotype DX) as predictors of response to neo-adjuvant chemotherapy in estrogen receptor positive (ER+), HER2 negative (HER2-) breast cancer. (2018) (1)
- 2106 POSTER Randomized clinical comparison of weekly or every-3-week 130-nanometer albumin-bound paclitaxel vs. every-3-week docetaxel as first-line therapy in patients with metastatic breast cancer (2007) (1)
- Trastuzumab-Induced Cardiotoxicity in Breast Cancer Patients (2010) (1)
- 2116 POSTER Nab-Paclitaxel weekly or Q3Wks compared to Docetaxel Q3Wks as first-line therapy in patients with metastatic breast cancer: an economic analysis of a prospective randomized trial (2007) (1)
- Burnout and career satisfaction among U.S. oncologists: Results of the 2012 ASCO survey. (2013) (1)
- Minimizing cancer's impact on bone with denosumab: Current and future perspectives (2013) (1)
- Prophylactic oophorectomy for patients with breast cancer with BRCA results. (2011) (1)
- Do hospitals in a large metropolitan area utilize published breast cancer care practices and guidelines? (2014) (1)
- Fertility Issues for Young Breast Cancer Patients (2014) (1)
- Is the Preoperative Setting an Appropriate Platform for Drug Approval in Breast Cancer? (2015) (1)
- Raloxifene vs Tamoxifen—Reply (2007) (1)
- Neoadjuvant therapy for stage III non-small-cell lung cancer : a review (1992) (1)
- Abstract P3-01-08: HER2-negative metastatic breast cancer with HER2-positive circulating tumor cells (CTCs): A new CTC-defined HER2-positive subgroup (2019) (1)
- P5-19-03: Albumin-Bound Paclitaxel (ab-pac) Versus Docetaxel for First-Line Treatment of Metastatic Breast Cancer (MBC): Overall Survival and Safety Analysis of a Randomized Phase II Trial. (2011) (1)
- Issues in Breast Cancer Survivorship: Optimal Care, Bone Health, and Lifestyle Modifications. (2016) (1)
- Validation of the Breast Cancer-specific Graded Prognostic Assessment (GPA) for Patients With Breast Cancer With Brain Metastases (2012) (1)
- Long-Term Cardiac Tolerability of Trastuzumab (2006) (1)
- Implications of first-line adjuvant treatment with aromatase inhibitors in recurrent metastatic breast cancer. (2004) (1)
- Are oncologists involved in cancer biomarker decisions at their institutions (2013) (1)
- 4R program results: What is the impact of 4R care delivery model on patient self-management and which patients benefited? (2020) (1)
- Abstract P4-01-04: ESR1 mutation in cell free DNA (cfDNA) is associated with significantly increased circulating tumor cell (CTC)-clusters and progress in stage III/IV breast cancer after systemic treatments (2019) (1)
- NCCN Breast Cancer Version 3 . 2014 Clinical Practice Guidelines in Oncology (2014) (1)
- Human epidermal growth factor receptor 2 (HER2): Translating the lab to the clinic (2016) (1)
- The AVADO Trial: Bevacizumab plus Docetaxel for Metastatic Breast Cancer (2010) (1)
- Update on fulvestrant for hormone receptor-positive advanced breast cancer (2007) (1)
- Optimizing the care of lung cancer patients: a multidisciplinary approach. (1990) (1)
- Abstract LB-370: A novelex vivoculture workflow to enrich and expand circulating tumor cells (CTCs) from patients with stage III/IV breast cancer (BCa) (2018) (1)
- Palliative Care for Cancer Patients (2009) (0)
- A spotlight on avoidance coping to manage fear of recurrence among breast cancer survivors in an eHealth intervention (2022) (0)
- Prolonged Adjuvant Aromatase Inhibitor Treatment for Early Breast Cancer (2018) (0)
- Which Breast Cancer Patients Should Receive Pertuzumab (2014) (0)
- Abstract P5-04-02: Progesterone receptor (PR) antagonism by telapristone acetate (TPA): A randomized, placebo-controlled phase IIB pre-surgical window trial in women with stage 0-II breast cancer (2019) (0)
- Management of Menopausal Symptoms in the Cancer Patient (1999) (0)
- Abstract PS10-24: Infusion related reactions in the phase 3 SOPHIA trial of margetuximab + chemotherapy vs trastuzumab + chemotherapy in patients with pretreated HER2+ metastatic breast cancer (2021) (0)
- Invasive Breast CancerPractice Guidelines in Oncology (2011) (0)
- Palbociclib plus Trastuzumab for HER2+ Advanced Breast Cancer (2020) (0)
- Time for 5-FU to Go! (2015) (0)
- Endocrine Cocktails for Advanced Breast Cancer (2012) (0)
- Ixabepilone shows promising clinical activity in metastatic breast cancer: Comment (2006) (0)
- Oncology and Hematology Top Stories of 2009 (2009) (0)
- Do CDK4/6 Inhibitors Improve Overall Survival in Advanced Breast Cancer? (2018) (0)
- Refining Treatment Decisions in Older Patients With Breast Cancer. (2015) (0)
- ESMO 2021 Report — Breast Cancer (2021) (0)
- A New Endocrine Agent for ER+/HER2− Breast Cancer (2018) (0)
- A third of refractory patients respond to trastuzumab-DM1: Commentary (2010) (0)
- 4R Care Delivery Program results: Impact of implementation metrics on patient self-management and 4R usefulness. (2020) (0)
- Restarting Adjuvant Endocrine Therapy for Breast Cancer (2017) (0)
- Does Prophylactic Contralateral Breast Mastectomy Prolong Survival (2010) (0)
- No Radiation-Delivery Bias in the Seminal ACOSOG Z0011 Trial (2014) (0)
- Abstract P2-14-01: Fulvestrant vs exemestane for treatment of metastatic breast cancer in patients with acquired resistance to non-steroidal aromatase inhibitors – a meta-analysis of EFECT and SoFEA (CRUKE/03/021 & CRUK/09/007) (2012) (0)
- The Epothilones Are Coming (2007) (0)
- Safety Profile of T-DM1 for Metastatic Breast Cancer (2014) (0)
- Time to Chemotherapy after Breast Cancer Surgery (2013) (0)
- The Next Big Thing for Metastatic Breast Cancer (2012) (0)
- Acknowledgment of Reviewers, 2018 (2018) (0)
- Selecting Patients for More Adjuvant Breast Cancer Therapy (2014) (0)
- PIK3CA Is Not a Useful Biomarker … Yet (2015) (0)
- KRAS Resistance: It's Complicated! (2021) (0)
- For Most with DCIS, Less Is More (2015) (0)
- Aromatase Inhibitors and Carpal Tunnel Syndrome (2016) (0)
- Vistusertib for ER-Positive Breast Cancer (2019) (0)
- Factors associated with CDK 4/6 inhibitor use for patients with advanced, hormone positive, HER-2-negative breast cancer. (2022) (0)
- First-Line Fulvestrant for Advanced Breast Cancer (2015) (0)
- Breast cancer survivors: Guidelines for follow-up care (1998) (0)
- ASCO 2009 Report: Breast Cancer (2009) (0)
- Is Trastuzumab Effective for Lobular Breast Cancers (2013) (0)
- Breast Irradiation and Cardiac Toxicity (2013) (0)
- Revisiting the Sequence of Adjuvant Chemotherapy and Endocrine Therapy in Breast Cancer (2011) (0)
- Male Breast Cancer: It's All About the Estrogen (2015) (0)
- Improving Libido in Postmenopausal Cancer Survivors (2007) (0)
- Raising the level of cancer care: Feasibility and reported benefit of a virtual tumor board. (2022) (0)
- Adjuvant Endocrine Therapy for Early Breast Cancer: The Story So Far (2010) (0)
- Abstract P4-01-18: Correlation between circulating tumor DNA (ctDNA) alterations and circulating tumor cells (CTC) uncovers new mechanisms of metastasis for patients with metastatic breast carcinoma (MBC) (2019) (0)
- Minimizing Bone Loss Related to Therapy with Aromatase Inhibitors (2008) (0)
- An Alternative Radiation Strategy for Early Breast Cancer (2017) (0)
- ASO Visual Abstract: Prognosis and Chemotherapy Use in Breast Cancer Patients with Multiple Lymphatic Micrometastases–An NCDB Analysis (2021) (0)
- Combined modality therapy for stage III non-small cell lung cancer : the University of Chicago experience (1991) (0)
- Biomarkers for Adjuvant Radiation Therapy in Early Breast Cancer (2018) (0)
- Reply to S. Sorscher. (2021) (0)
- Pumping Iron, Physical Function, and Breast Cancer Survivors (2015) (0)
- Abstract PS2-05: Genetic profiling for circulating tumor cell clusters to unveil molecular drivers of metastasis (2021) (0)
- Artificial Intelligence to Assess Hormonal Status of Breast Cancer Patients (2019) (0)
- High BMI Increases Risk of Second Cancers in Women with Breast Cancer (2021) (0)
- Author's reply to Lamy. (2013) (0)
- CHF in Older Women After Adjuvant Anthracycline-Based Chemotherapy for Breast Cancer (2007) (0)
- Relationship of pathological features and a 21 gene expression assay in young women with early breast cancer. (2017) (0)
- PARP Inhibitor for Metastatic Breast Cancer (2017) (0)
- Distinguishing Between Invasive Ductal and Lobular Carcinoma (2008) (0)
- Optimizing Cytotoxic Chemotherapy: New Insights (2007) (0)
- Practice-Changing Interventions in the Systemic Management of Breast Cancer (2020) (0)
- Another Antibody Drug Conjugate for Breast Cancer (2019) (0)
- Breast Radiation: Shorter as Good as Longer (2013) (0)
- Abstract PD14-01: Comprehensive molecular characterization of patients with metastatic invasive lobular carcinoma (ILC): Using real-world data to describe this unique clinical entity (2022) (0)
- Roundtable discussion: Current standard of care for adjuvant hormonal treatment of breast cancer (2005) (0)
- Abstract B141: Landscape of circulating tumor DNA (ctDNA) in refractory metastatic breast cancer:Real-timeevaluation of treatment-resistance (2019) (0)
- Objectively-Measured Physical Activity in Breast Cancer Patients Undergoing Chemotherapy (2019) (0)
- Adjuvant Systemic Therapy for Breast Cancer: An Overview (2010) (0)
- Breast Cancer May Be Biologically Different in Men Than in Women (2019) (0)
- Does Obesity Attenuate Aromatase Inhibition (2012) (0)
- Effect of Diet and Physical Activity on Breast Cancer Survival (2007) (0)
- Host Immunity and Triple-Negative Breast Cancer (2014) (0)
- Switching to Exemestane After Tamoxifen Improves Breast Cancer Outcomes (2007) (0)
- Patterns of Recurrence in Node-Negative Breast Cancer (2013) (0)
- 0065 Predictive factors for response to fulvestrant - the impact of prior endocrine response on treatment outcome (2009) (0)
- Developments in Adjuvant Therapy for Early-Stage Breast Cancer: Endocrine Therapy for Premenopausal Women and Small HER2- Positive Tumors (2015) (0)
- A Targeted Agent for Triple-Negative Breast Cancer (2015) (0)
- Phase II study of gemcitabine (Gem) + docetaxel (D) in combination with trastuzumab (T) in patients (pts) with HER2-overexpressing metastatic breast cancer (MBC). (2006) (0)
- Markers of Risk for Bone Metastases in Breast Cancer (2011) (0)
- Forest or Trees? The Consequences of Aggregating Data from Diverse Populations (2021) (0)
- Pregnancy and Breast Cancer (2013) (0)
- Avoiding Chemotherapy in HER2-Positive Breast Cancer (2013) (0)
- Body mass index (BMI), tumor subtype, and relapse-free survival (RFS) in CALGB 9741 (Alliance). (2013) (0)
- Precisely Choosing Breast Cancer Therapy (2014) (0)
- Abstract PD14-04: Circulating tumor DNA characterization of invasive lobular carcinoma in patients with metastatic breast cancer (2022) (0)
- Endocrine Therapy plus Bevacizumab for Advanced Breast Cancer (2015) (0)
- Doxorubicin or Docetaxel for Operable Breast Cancer (2006) (0)
- Ovarian Suppression in Patients with Hormone-Receptor–Positive Breast Cancer (2016) (0)
- HER2 Testing in Breast Cancer (2013) (0)
- Delaying Radiation Therapy After Breast-Conserving Surgery (2009) (0)
- Computational ranking-assisted identification of Plexin-B2 in homotypic and heterotypic clustering of circulating tumor cells in breast cancer metastasis (2023) (0)
- Trastuzumab and Cardiac Monitoring in Breast Cancer (2015) (0)
- Contents Vol. 58, 2000 (2000) (0)
- Late Risk for Recurrence with Estrogen Receptor–Positive Breast Cancer (2016) (0)
- Abstract PD1-02: Circulating tumor DNA (ctDNA): Areal-timeapplication of precision medicine to the management of metastatic breast cancer (MBC) (2017) (0)
- Are Anthracyclines Justified for Breast Cancer (2009) (0)
- Challenges to Optimal Local Therapy in Breast Cancer (2015) (0)
- Abstract GS3-10: Study of samuraciclib (CT7001), a first-in-class, oral, selective inhibitor of CDK7, in combination with fulvestrant in patients with advanced hormone receptor positive HER2 negative breast cancer (HR+BC) (2022) (0)
- ASCO 2008 Report: Breast Cancer (2008) (0)
- High-dose chemotherapy and autologous stem cell transplantation as treatment for high-risk breast cancer (2009) (0)
- Acupuncture for Cancer-Related Fatigue in Breast Cancer Survivors (2013) (0)
- How Well Do Breast Cancer Patients Adhere to Adjuvant Therapy (2009) (0)
- T-DM1 for HER2-Positive Breast Cancer (2013) (0)
- Recognizing Endocrine Disorders: A Required Skill Set for Immuno-Oncology (2018) (0)
- Does the innovative 4R Care Delivery Model improve timing and sequencing of guideline recommended breast cancer care in safety net and non-safety net centers? (2019) (0)
- Molecular Interrogation of Estrogen-Receptor–Positive Breast Cancer (2016) (0)
- Addressing Fertility: an Essential Aspect of Comprehensive Care for Young Patients with Breast Cancer (2020) (0)
- Updated Recommendations for Breast Cancer Surveillance in Young Female Cancer Survivors (2021) (0)
- Breast Density: A Marker of Tamoxifen's Preventive Benefit? (2011) (0)
- Adjuvant Goserelin for Early-Stage Breast Cancer (2009) (0)
- DDDT-3122-management of advanced breast cancer (2009) (0)
- What Is the Optimal Neoadjuvant Taxane Therapy for Breast Cancer (2019) (0)
- Another Reason Not to Test for CYP2D6 (2015) (0)
- Abstract 2646: The liquid biopsy network in advanced breast cancer (ABC): Benchmarking the prognostic role of circulating tumor DNA (ctDNA) to the goal standard circulating tumor cells (CTCs) enumeration (2018) (0)
- Neoadjuvant CDK4/6 Inhibition for ER-Positive Breast Cancer (2017) (0)
- Abstract 1351: A novel application of DEPArrayTMNxT System to isolate circulating tumor cell (CTC)-clusters from patients with metastatic breast cancer (MBC) (2019) (0)
- Two Breast Cancer Drugs Graduate from Novel Trials (2016) (0)
- Little Benefit to Extensive Breast Cancer Monitoring (2016) (0)
- Is Radiotherapy Unnecessary for Some Breast Cancer Patients (2015) (0)
- Mechanism of ER-Negative Breast Cancer in (2007) (0)
- Key Takeaways Related to HER2 Therapy (2013) (0)
- Trastuzumab Monotherapy for Older Patients with Early HER2+ Breast Cancer? (2020) (0)
- Adjuvant Bisphosphonates for Patients with Breast Cancer (2017) (0)
- Optimizing survival in patients with advanced and metastatic breast cancer: Individualizing therapy (2014) (0)
- Older women can safely bypass radiation for early-stage disease: Comment (2010) (0)
- Breast Cancer Chemoprevention for (2013) (0)
- Abstract OT1-1-09: ALTERNATIVE (EGF114299): A study of lapatinib, trastuzumab, and endocrine therapy in patients who received neo-/adjuvant trastuzumab (IV) and endocrine therapy (2013) (0)
- Biosimilar Trastuzumab for HER2-Positive Breast Cancer (2018) (0)
- Combination of lapatinib and capecitabine provides significant benefit in metastatic disease: Comment (2006) (0)
- Long-Term Toxicities of Selective Estrogen-Receptor Modulators and Antiaromatase Agents (2003) (0)
- Adding carboplatin fails to boost efficacy of docetaxel and trastuzumab: Comment (2006) (0)
- Lidocaine for Dyspareunia in Breast Cancer Survivors (2015) (0)
- Clinical and Pathologic Factors Matter in Decision Making for Breast Cancer Care (2021) (0)
- Circulating tumor cells (CTCs) and circulating tumor DNA (ctDNA) longitudinal monitoring of metastatic breast cancer (MBC). (2016) (0)
- A phase II trial of capecitabine (C) in combination with the farnesyltransferase (FT) inhibitor (FTI), tipifarnib (T), in patients (pt) with metastatic breast cancer (MBC): ECOG trial 1103 (2007) (0)
- Age-Related Toxicity of Trastuzumab (2014) (0)
- Dietary Fat Intake and Risk for Postmenopausal Breast Cancer (2007) (0)
- Platinum Chemo for (2017) (0)
- Duration of Adjuvant Trastuzumab for HER2-Positive Breast Cancer (2013) (0)
- Late Cardiac Events Rare After Adjuvant Trastuzumab for Breast Cancer (2012) (0)
- Supporting patients with metastatic breast cancer: A call to action (2008) (0)
- Advances in Breast Cancer Management, Second Edition (2008) (0)
- Care delivery barriers to personalized medicine in breast cancer. (2010) (0)
- Radiotherapy for Breast Cancer: Long-Term Consequences (2017) (0)
- Abstract P5-03-11: Possible role for cancer stem cells: results from a pilot neoadjuvant trial of HER-2 positive breast cancer patients treated with a combination of (Nab)-paclitaxel and lapatinib. (2012) (0)
- In the pipeline: Trastuzumab-DM1 active after HER2 therapy fails - Commentary (2009) (0)
- Abstract PS2-26: Evaluating the pathogenicity of emerging genomic aberrations detected by circulating tumor DNA over the course of metastatic breast cancer (2021) (0)
- Circulating tumor DNA (ctDNA) to evaluate stage III and stage IV metastatic breast cancer (MBC), describe tumor heterogeneity, and outcome. (2020) (0)
- Extending Aromatase Inhibitor Therapy for Early Breast Cancer (2016) (0)
- Characterizing unique supportive care needs among women living with metastatic breast cancer: A qualitative study (2023) (0)
- Trastuzumab for HER2 Early Breast Cancer: Long-Term Follow-Up (2017) (0)
- Fitting Fulvestrant into the Sequence of Treatments for Metastatic Breast Cancer (2010) (0)
- Top Stories of 2014 (2014) (0)
- ASCO 2010 Report: Breast Cancer (2010) (0)
- Abstract P5-01-10: Next generation sequencing-based gene variant-oriented characterization in metastatic breast cancer: An innovative analysis using ctDNA (2020) (0)
- Predicting Late Recurrence of Breast Cancer (2014) (0)
- Paradigm Shift in Adjuvant Treatment of Receptor Positive Premenopausal Breast Cancer Patients ? Not Yet ! (2003) (0)
- Adjuvant CDK4/6 Inhibitor in High-Risk Early-Stage Breast Cancer (2021) (0)
- Fatigue and Breast Cancer (2020) (0)
- The AI War is Over: It's a Tie (2013) (0)
- Changes in circulating endothelial and tumor cells may mark anti-angiogenesis. Comment (2005) (0)
- Retrospective analysis of patients with poor prognostic factors and metastatic breast cancer in a phase III study comparing nab-paclitaxel to solvent-based paclitaxel (2008) (0)
- Introduction: Skeletal Issues and Bone Health in Patients With Cancer (2009) (0)
- Chemotherapy for Breast Cancer Patients with High Recurrence Scores (2020) (0)
- Immunotherapy for Breast Cancer Has Arrived (2018) (0)
- Clinical Utility of New Antiestrogens (2009) (0)
- Skip axillary dissection when sentinel node is negative: Comment (2010) (0)
- Abstract P2-02-21: The utility and correlation of circulating tumor cells (CTCs) and cell-free circulating tumor DNA (ctDNA) based on HER2 positivity (2018) (0)
- Use of the CTC Count in Treatment Decisions for Metastatic Breast Cancer (2021) (0)
- Breast density taking center stage in legislative agendas: Commentary (2011) (0)
- Ovarian Suppression for Young Women with Breast Cancer (2015) (0)
- Dual Targeting of HER2-Positive Breast Cancer (2017) (0)
- Can Anthracycline Response Be Predicted from (2009) (0)
- Circulating tumor cells enumeration (CTCs) and circulating tumor DNA (ctDNA): Clinical and molecular features of “rapidly progressing” stage IV disease (Stage IVprog). (2018) (0)
- Exemestane for Premenopausal Breast Cancer (2014) (0)
- Gene Signatures Predict Response to Cancer Therapy (2007) (0)
- ASCO 2016 Report — Breast Cancer (2016) (0)
- Is Hormone Therapy Safe for (2008) (0)
- Choosing Chemotherapy in Triple-Negative Breast Cancer Based on Homologous Recombination Deficiency (2021) (0)
- Immunohistochemistry on sentinel nodes does not yield additional prognostic data: Comment (2010) (0)
- Does Adding a Targeted Agent Improve Neoadjuvant Endocrine Therapy for Breast Cancer (2019) (0)
- Neratinib + capecitabine sustains health-related quality of life in patients with HER2-positive metastatic breast cancer and ≥ 2 prior HER2-directed regimens (2021) (0)
- Vitamin D Levels and Breast Cancer Outcome (2016) (0)
- Is lobular breast cancer different and should it be treated differently? (2021) (0)
- Molecular Signature for Platinum Sensitivity in Breast Cancer (2018) (0)
- Striking Back at Trastuzumab Resistance in Breast Cancer (2011) (0)
- Protective Effect of Oophorectomy in BRCA Mutation Carriers (2014) (0)
- Predicting Efficacy of Adjuvant Tamoxifen for Early-Stage Breast Cancer (2019) (0)
- How to Manage Complications of ADT (2018) (0)
- Abstract PD8-03: Clinico-pathological and molecular features in young women with metastatic breast cancer (2020) (0)
- Switching from tamoxifen to exemestane in localized breast cancer: Four representative case studies (2006) (0)
- Targeting the Androgen Receptor in Triple-Negative Breast Cancer (2018) (0)
- Chemo edges out hormonal therapy at neoadjuvant stage: Comment (2010) (0)
- BRCA Testing in Community Practice (2015) (0)
- Adjuvant Radiation Therapy for Breast Cancer Affects Coronary Arteries (2012) (0)
- Neoadjuvant Therapy with Trastuzumab Emtansine for HER2-Positive Breast Cancer (2021) (0)
- RIBBON-1: Avastin raises PFS, not overall survival - Commentary (2009) (0)
- In Breast Cancer, Not All Small Tumors Are Equal (2010) (0)
- Distant metastasis and death more likely in obese women: Commentary (2010) (0)
- Mutation-Directed Therapy for Metastatic Breast Cancer (2020) (0)
- Abstract 429: Increased chromatin heterogeneity in circulating tumor cells (CTCs) is associated with high levels of HER2 expression in metastatic breast cancer (MBC) (2019) (0)
- Trials of Tamoxifen for Breast Cancer Prevention (2007) (0)
- More Uncertainty About Platinum Chemotherapy for (2020) (0)
- Relieving Hot Flashes in Breast Cancer Survivors (2011) (0)
- Another Strike Against Antiangiogenic Therapy for Breast Cancer (2013) (0)
- Multimodal DCIS therapy with tamoxifen cuts breast ca deaths: Commentary (2011) (0)
- Association of breast cancer in men with exposure to 5-α reductase inhibitors: A RADAR report. (2012) (0)
- Capecitabine for Postsurgical Residual Breast Cancer (2017) (0)
- PARP inhibitors target triple-negative, BRCA1/2 cancers: Commentary (2009) (0)
- Exercise After Breast Cancer: A Prescription for Survivorship (2016) (0)
- Plasma Prolactin Levels Influence Breast Cancer Development (2007) (0)
- Lapatinib/trastuzumab slows heavily pretreated HER2+ MBC: Commentary (2008) (0)
- Brachytherapy for Breast Cancer: Maybe Not So Good (2012) (0)
- Olanzapine for Chronic Nausea in Patients with Advanced Cancer (2020) (0)
- Which Breast Cancer Patients Benefit from Everolimus (2016) (0)
- Preoperative Systemic Therapy for Breast Cancer (2014) (0)
- Trastuzumab Keeps On Giving (2011) (0)
- A Signature for Trastuzumab Benefit in HER2-Positive Breast Cancer? (2015) (0)
- New Insights About Trastuzumab for HER2-Positive Early Breast Cancer (2011) (0)
- Abstract P1-16-08: Response to subsequent therapy after dual immune checkpoint blockade in metastatic breast cancer (2019) (0)
- Who Needs a Taxane? Tailoring Breast Cancer Therapy (2007) (0)
- A Possible Target in Triple-Negative Breast Cancer (2017) (0)
- Breast Cancer Vaccines as Therapy: Another Chapter (2015) (0)
- Racial Differences and Preoperative Therapy for Breast Cancer (2015) (0)
- Novel Neoadjuvant Treatment Strategies for Triple-Negative Breast Cancer. (2020) (0)
- Postmastectomy recurrence rates low without radiation: Commentary (2010) (0)
- Exemestane prevents 65% of invasive Ca post menopause: Commentary (2011) (0)
- High-Dose Chemotherapy for Breast Cancer (1997) (0)
- Top Stories of 2016 (2016) (0)
- Can the enumeration of circulating tumor cells (CTCs) and the characterization of circulating tumor DNA (ctDNA) provide insight into organ tropism in metastatic breast cancer (MBC)? (2019) (0)
- Abstract P4-01-08: Characterization of circulating tumor free DNA (ctDNA) obtained from patients with metastatic breast carcinoma (MBC) undergoing systemic therapies using comprehensive genomic profiling (2019) (0)
- Abstract C022: Integrated molecular approach to identify biologic factors contributing to breast cancer disparities in Chicago (2019) (0)
- Biopsy of Recurrent Breast Cancer Can Tell an Important Story (2012) (0)
- Caring for the breast cancer survivor (1999) (0)
- Cardiac Consequences for Breast Cancer Survivors Treated with Trastuzumab (2020) (0)
- Hip fractures as a complication of cancer care in perimenopausal women with breast cancer. (2010) (0)
- Randomized comparisons of weekly versus every-3-week nab-paclitaxelin patients with metastatic breast cancer (2008) (0)
- Sorafenib for Metastatic Breast Cancer (2009) (0)
- Abstract P3-01-10: Associations between plasma Interleukin 2 (IL-2) and HER2 expression in circulating tumor cell (CTC) and MYC alterations in circulation tumor DNA (ctDNA) open a new insight on immune microenvironment for patients with metastatic breast cancer (MBC) (2019) (0)
- Predicting Late Recurrences in Breast Cancer (2013) (0)
- Axillary Lymph Node Nanometastases (2006) (0)
- Physician Attitudes About Genomic Testing (2014) (0)
- Who Needs Extended Endocrine Therapy for HR+ Breast Cancer? (2020) (0)
- Abstract OT3-01-01: A phase II study of PD-L1 and CTLA-4 inhibition and immunopharmcogenomics in metastatic breast cancer (2017) (0)
- ASCO 2013 Report — Breast Cancer (2013) (0)
- No Role for CYP2D6 or UGT2B7 Testing in Breast Cancer (2012) (0)
- ERBB2 amplifications and mutations in 109 advanced breast cancer patients by next-generation sequencing. (2020) (0)
- Grappling with Racial Disparities in Breast Cancer (2013) (0)
- ASCO 2015 Report — Breast Cancer (2015) (0)
- Lapatinib in HER2+ early breast cancer: Quality of life analysis. (2012) (0)
- Fewer Patients with Breast Cancer Require Chemotherapy (2018) (0)
- Radiotherapy Benefit Confirmed in Patients Undergoing Breast Conservation (2014) (0)
- Abstract PS2-20: Prognostic value of baseline circulating tumor cells (CTCs) enumerations is for stage III and stage IV breast cancer (2021) (0)
- The role of aromatase inhibitors as first- and second-line therapy for hormone-sensitive metastatic breast cancer (2003) (0)
- The Breast Itself as a Prognostic Factor for Cancer Risk (2010) (0)
- Optimal Timing of Adjuvant Chemotherapy Following Breast Cancer Surgery (2006) (0)
- 244PDEverolimus (EVE) + letrozole (LET) in patients (pts) with estrogen receptor-positive (ER+), human epidermal growth factor receptor 2-negative (HER2−) advanced breast cancer (ABC): Progression-free survival (PFS) subgroup analyses in BOLERO-4 (2017) (0)
- The impact of BRCA testing on surgical treatment decisions for patients with breast cancer (2011) (0)
- HER2-Directed Therapy for Advanced Breast Cancer (2014) (0)
- Functional Limitations in Women with Breast Cancer (2010) (0)
- Breast Cancer Risk Reduction , Version 2 . 2015 Clinical Practice Guidelines in Oncology (2015) (0)
- Dual Antibodies Reap Benefits Against HER2-Positive Metastatic Breast Cancer (2012) (0)
- How well is interdependent care managed across specialties in breast cancer? Metrics and pre-implementation data from the 4R in Oncology Project. (2017) (0)
- Strategies for Preventing Breast Cancer Brain Metastases (2015) (0)
- Older breast cancer patients can forego RT. Comment (2005) (0)
- Phase II Trial of Capecitabine and Weekly Paclitaxel as First-Line Therapy for Metastatic Breast Cancer (2007) (0)
- Long-Term Outcomes of Ductal Carcinoma in Situ (2011) (0)
- Raloxifene vs tamoxifen. Authors' reply (2007) (0)
- Association of HER2 alterations and ESR1 mutations in cell-free DNA (cfDNA) with circulating tumor cells (CTCs), multiple metastasis, and prognosis in stage III/IV breast cancer (BCa). (2019) (0)
- Tracking Tumor Perfusion in Locally Advanced Breast Cancer (2008) (0)
- Bone mineral density and FRAX as predictors of fracture risk in women with breast cancer. (2013) (0)
- Another Helping of Flaxseed for Breast Cancer (2011) (0)
- Lapatinib for Treatment of Metastatic Brain Metastases (2008) (0)
- Fertility Preservation in Patients With Breast Cancer (2016) (0)
- Pembrolizumab for ER+/HER2− Metastatic Breast Cancer (2018) (0)
- Long-Term Benefit of Tamoxifen Chemoprevention (2015) (0)
- Long-term hazard of recurrence in HER2+ breast cancer patients untreated with anti-HER2 therapy (2015) (0)
- Tumor Heterogeneity Challenges Targeted Therapy (2012) (0)
- Broadening Chemotherapy Options for Metastatic Breast Cancer (2010) (0)
- Bad Breast Cancer on the Rise in Young Women (2013) (0)
- ASCO 2021 Meeting Report: Breast Cancer (2021) (0)
- Predisposition Genes for Breast Cancer (2021) (0)
- The Impact of Copay on Adherence to Breast Cancer Medications (2015) (0)
- Assessing Cancer Risks in (2015) (0)
- Insights into Male Breast Cancer (2019) (0)
- Adjuvant therapy for breast cancer: Hormonal therapy (2015) (0)
- Improving Sexual Health in Breast Cancer Survivors (2016) (0)
- Moving the Needle: Improvements in Breast Cancer Outcomes (2014) (0)
- Paclitaxel matches nab-paclitaxel, passes ixabepelone: Commentary (2012) (0)
- Commentary (Kaklamani/Gradishar): Adjuvant Hormonal Therapy in Early Breast Cancer (2005) (0)
- HER2 gene amplification predicts response to lapatinib: Commentary (2008) (0)
- Bevacizumab for Breast Cancer: What's Next? (2012) (0)
- Abstract P5-17-02: Dissecting the biology of inflammatory breast cancer (BC) through cell free DNA and a circulating tumor cells (CTC)-derived signature (2019) (0)
- High-Dose Chemotherapy and Breast Cancer . . . One More Time! (2007) (0)
- Rethinking Tamoxifen: Is Longer-Duration Therapy Better? (2012) (0)
- ASCO 2017 Report — Breast Cancer (2017) (0)
- Postmastectomy radiation for young woman with poorly differentiated adenocarcinoma of the breast (2000) (0)
- Regional nodal irradiation combats disease recurrence: Commentary (2011) (0)
- Proton-Beam Radiation Therapy for Breast Cancer (2019) (0)
- Monoclonal antibody to RANK-L shows bone protection potential: Comment (2006) (0)
- Adjuvant Bisphosphonate for Early-Stage Breast Cancer (2009) (0)
- Biopsies of New Metastatic Lesions in Breast Cancer (2009) (0)
- Which Patients Benefit from Neoadjuvant Therapy for Breast Cancer (2012) (0)
- Alert Will Be Sent on Tuesdays (2007) (0)
- Treatment Delay and Breast Cancer Outcomes (2013) (0)
- Abstract C23: Phase 3 trial comparing capecitabine in combination with sorafenib or placebo for treatment of locally advanced or metastatic HER2-negative breast cancer (RESILIENCE). (2011) (0)
- Abstract P1-18-04: Phase 3 SOPHIA study of margetuximab + chemotherapy vs trastuzumab + chemotherapy in patients with HER2+ metastatic breast cancer after prior anti-HER2 therapies: Infusion time substudy results (2020) (0)
- Preop vs. Postop Chemotherapy for Breast Cancer (2007) (0)
- Abstract P3-01-05: Liquid biopsy methods and machine learning modeling to understand organ tropism and metastatization behavior of metastatic breast cancer (2020) (0)
- ASCO 2012 Report: Breast Cancer (2012) (0)
- Does Pregnancy Affect Outcomes in Women with Breast Cancer (2017) (0)
- Dual HER2 blockade boosts survival in metastatic cases: Commentary (2010) (0)
- Abstract 1176: Racial differences in circulating inflammatory cytokines and breast cancer disparities (2020) (0)
- Antiinflammatory Use and Postmenopausal Breast Cancer Risk (2012) (0)
- Consequences of Factor V Leiden Mutation in Patients Treated with Adjuvant Tamoxifen (2010) (0)
- Top Stories of 2018 (2018) (0)
- Cardiac Toxicity Among Breast Cancer Patients in Routine Practice (2016) (0)
- Equivalent efficacy for exemestane and anastrozole in advanced breast cancer: Comment (2006) (0)
- Abstract P2-02-05: Dynamic circulating tumor cell changes in enumeration and HER2 expression during systemic therapy for metastatic breast cancer (2022) (0)
- Do breast cancer treatment and imaging providers follow hereditary breast and ovarian cancer risk screening guidelines (2014) (0)
- Does Metformin Reduce Risk for Breast Cancer (2012) (0)
- Expedition Inspiration Fund for Breast Cancer Research Meeting 2003 (2003) (0)
- Will breast cancer survivors receive the same content and assessment in survivorship care plans at non-COC sites? (2015) (0)
- Osteonecrosis of the Jaw and Breast Cancer Treatment (2013) (0)
- Is Pregnancy Safe After Breast Cancer (2018) (0)
- Updated Guidelines for Treatment of Advanced HER2-Positive Breast Cancer (2018) (0)
- Are Circulating Tumor Cells Predictive of Late Recurrence of ER-Positive Breast Cancer? (2019) (0)
- Abstract PS2-08: Identification of incidental putative germline variants in circulating tumor DNA (2021) (0)
- Abstract P2-11-09: Characterization of metastatic breast cancer through a novel next generation sequencing platform for hypothesis generation on endocrine resistance (2020) (0)
- AVADO: Bevacizumab/docetaxel provides small benefit in PFS. Commentary (2008) (0)
- ASCO 2018 Report — Breast Cancer (2018) (0)
- Neratinib for Metastatic HER2 Breast Cancer (2014) (0)
- Medical Oncology, The Medical Oncology Centre of Rosebank, Johannesburg, (2014) (0)
- Yoga and Breast Cancer Survivor Quality of Life (2014) (0)
- Clinical Outcomes in Patients with Residual DCIS After Neoadjuvant Chemotherapy (2007) (0)
- ASCO 2014 Report — Breast Cancer (2014) (0)
- Do breast cancer treatment and imaging providers follow hereditary breast and ovarian cancer risk screening guidelines? (2014) (0)
- Adjuvant Chemotherapy for Small Breast Cancers (2020) (0)
- Improving Prediction of Breast Cancer Recurrence (2011) (0)
- A multi-site trial of an electronic health integrated physical activity promotion intervention in breast and endometrial cancers survivors: MyActivity study protocol. (2023) (0)
- High-Dose Fulvestrant for Advanced Breast Cancer (2014) (0)
- CONFIRM trial: Fulvestrant 500 mg better than standard dosing: Commentary (2010) (0)
- Abstract P4-01-08: Anatomical staging and value of CTCs in locally advanced breast cancer (LABC) and metastatic breast cancer (MBC) (2020) (0)
- The Effect of Food on Lapatinib Bioavailability (2009) (0)
- Predicting Breast Cancer Treatment Futility with PET (2015) (0)
- Pharmacogenomics of Tamoxifen: Can Therapeutic Outcomes Be Tailor Made? (2020) (0)
- Oncology and Hematology Top Stories of 2012 (2012) (0)
- NEJM Journal Watch Oncology and Hematology Top Stories of 2015 (2015) (0)
- Anti HER2 therapy and endocrine therapy (The 49th annual meeting of Japanese Society of Clinical Oncology educational book) -- (JSCO University: Breast cancer) (2011) (0)
- Abstract PS2-10: Circulating tumor DNA (ctDNA) as a diagnostic tool to identify putative germlineBRCAmutations (2021) (0)
- Did the WHI Results Affect Breast Cancer Incidence (2007) (0)
- Abstract PS9-11: Health-related quality of life for margetuximab + chemotherapy vs. trastuzumab + chemotherapy in the phase 3 SOPHIA trial of patients with pretreated HER2+ metastatic breast cancer (2021) (0)
- Long-Acting Formulation of Irinotecan for Breast Cancer (2015) (0)
- Top Stories of 2017 (2017) (0)
- Triplet Therapy for HER2+ Metastatic Breast Cancer and Brain Metastases (2020) (0)
- An Anti–Trop-2 Antibody–Drug Conjugate for Triple-Negative Breast Cancer (2017) (0)
- Top Stories of 2020 (2020) (0)
- Antiangiogenic Therapy for Breast Cancer: One Step Forward, Two Steps Back? (2008) (0)
- ASCO 2011 Report: Breast Cancer (2011) (0)
- Adjuvant Trastuzumab for HER2-Positive Breast Cancer (2007) (0)
- Congestive Heart Failure with Adjuvant Trastuzumab for Breast Cancer (2016) (0)
- Male breast cancer as a second primary cancer (SPC): Increased risk following hematologic malignancies. (2015) (0)
- ATAC at 100! (Months) (2008) (0)
- When Biology Bests Clinical Assumptions About Breast Cancer (2011) (0)
- Targeting HER2-positive metastatic breast cancer with ARX788, a novel anti-HER2 antibody-drug conjugate in patients whose disease is resistant or refractory to T-DM1, and/or T-DXd, and/or tucatinib-containing regimens. (2022) (0)
- Meeting Report: The 2008 San Antonio Breast Cancer Symposium (2009) (0)
- Systemic Treatment Unsuccessful for Breast Cancer–Related Brain Metastases (2016) (0)
- Abstract OT3-1-06: A phase 2 single-arm study to evaluate the clinical activity, safety and tolerability of enzalutamide (ENZA) with trastuzumab in patients with advanced human growth factor receptor 2 (HER2)-positive breast cancer (2015) (0)
- The Kumar/Leonard article reviewed (2005) (0)
- The Genomic Landscape of Invasive Lobular Breast Cancer (2016) (0)
- Gene-Expression Assay Prognostic in Breast Cancer (2015) (0)
- Breast cancer outcomes (2018) (0)
- JNCCN NCCN Task Force Report : Adjuvant Therapy for Breast Cancer — Clarification and Expansion of NCCN Clinical Practice Guidelines (2006) (0)
- What About “Endo-Brain”? (2014) (0)
- The Castiel article reviewed (1999) (0)
- ESMO 2020 Report — Breast Cancer (2020) (0)
- T-DM1 Prolongs Survival in Advanced HER2-Positive Breast Cancer (2012) (0)
- Another Tool to Help Breast Cancer Patients Avoid Chemotherapy (2016) (0)
- HIGH-DOSE CHEMOTHERAPY FOR BREAST CANCER. AUTHOR'S REPLY (1997) (0)
- Crossover order does not affect survival in metastatic patients: Commentary (2009) (0)
- Oncology and Hematology Editors' Choice: Top Stories of 2013 (2013) (0)
- Adjuvant Bevacizumab for Triple-Negative Breast Cancer (2017) (0)
- ESR1 mutations in circulating tumor DNA (ctDNA) are associated with CTCs and increased hormone receptors in metastatic tumor tissues of patients with metastatic breast cancer (MBC). (2022) (0)
- The Next Wave of Microtubule-Targeting Agents: Epothilones (2008) (0)
- Preoperative MRI of Little Benefit in Newly Diagnosed Breast Cancer (2014) (0)
- Neratinib for HER2-Positive Breast Cancer: 5-Year Outcomes (2017) (0)
- Guideline Update: Fertility Preservation for Patients with Cancer (2013) (0)
- Stopping Chemoprevention Before Realizing the Benefit (2017) (0)
- Preoperative Trastuzumab, Docetaxel, and Carboplatin for HER2-Positive Breast Cancer (2007) (0)
- Adjuvant Biologic Agents for Breast Cancer (2015) (0)
- Gender and the Tolerability of Anti–PD-1 Therapy (2018) (0)
- Raloxifene is as effective as tamoxifen in preventing primary invasive breast cancer: Comment (2006) (0)
- Insights into Therapy for BRCA1-Associated Breast Cancers (2010) (0)
- Abstract P5-17-03: How is inflammatory breast cancer (IBC) different? Integration of clinico-pathological features and circulating tumor cells (CTCs)-based biomarkers for disease and prognostic assessment (2019) (0)
- Endocrine Treatment Toxicity in Breast Cancer: A Good Thing? (2013) (0)
- 273TiP ACE-Breast-03: A phase II study patients with HER2-positive metastatic breast cancer whose disease is resistant or refractory to T-DM1, and/or T-DXd, and/or tucatinib-containing regimens treated with ARX788 (2022) (0)
- In Making Choices Regarding Early Breast Cancer, More Is Not Always Better (2021) (0)
- mTOR Inhibitors in Breast Cancer: Not the Answer for All (2013) (0)
- The evolving role of endocrine therapy for the treatment and prevention of breast cancer. (2002) (0)
- Abstract P4-01-14: Association between interleukin 2 (IL-2) and circulating tumor DNA (ctDNA) is a novel biomarker for patients with metastatic breast cancer (BCa) after systemic therapies (2019) (0)
- It Takes a Village for Weight Loss (2015) (0)
- Newer Strategies for Overcoming Endocrine Resistance (2014) (0)
- Where Do Breast Cancer Cells Hide (2016) (0)
- A pilot phase II trial of cabergoline in the treatment of metastatic breast cancer. (2017) (0)
- The landscape of genomic alterations detected in serial circulating tumor DNA (ctDNA) in clinical progressive metastatic breast cancer. (2020) (0)
- Adjuvant Chemotherapy for Early-Stage Breast Cancer (2009) (0)
- Oncology and Hematology Top Stories of 2010 (2010) (0)
- Lapatinib for HER2-Positive Breast Cancer Patients (2007) (0)
- A Novel Treatment for Triple-Negative Breast Cancer? (2014) (0)
- OlympiA: Game Changer for Breast Cancer Treatment (2021) (0)
- OT1-02-03: EGF114299: Safety and Efficacy of an Aromatase Inhibitor (AI) in Combination with Lapatinib (L), Trastuzumab (T) or Both for the Treatment of Hormone Receptor-Positive (HR+), HER2+ Metastatic Breast Cancer (MBC). (2011) (0)
- Will Chemotherapy Make Me Old (2014) (0)
- Abstract PS2-33: Investigating oncogenic signaling pathways in inflammatory metastatic breast cancer (MBC) though circulating tumor DNA (ctDNA) next-generation sequencing (NGS) (2021) (0)
- In reply [7] (2007) (0)
- 4R program results in breast cancer: The impact of 4R Care Delivery Model on timing and sequence of guideline recommended care. (2020) (0)
- Abstract P2-08-04: Progressive metastatic breast cancer with no detectable circulating tumor DNA: Evaluating limitations of this highly sensitive tool (2022) (0)
- Formulating guidelines for chemotherapy in advanced breast cancer (1999) (0)
- Abstract PD6-08: Exploring the interplay among ESR1/PIK3CA codon variants, oncogenic pathway alterations and clinical phenotype of metastatic breast cancer (MBC) through circulating tumor DNA (ctDNA) next-generation sequencing (NGS) (2022) (0)
- Refining the Evaluation of Axillary Node Metastases (2016) (0)
- Support for continuing trastuzumab after breast cancer progression: Commentary (2008) (0)
- The Next Adjuvant Therapy for Breast Cancer (2009) (0)
- Avoiding Adjuvant Anthracylines for HER2-Positive Breast Cancer (2011) (0)
- “Chemo Brain” Is Real (2017) (0)
- Subject Index Vol. 58, 2000 (2000) (0)
- Omission of Axillary Dissection for Minimal Node-Positive Breast Cancer (2018) (0)
- Does the innovative 4R Cancer Care Delivery Model improve patient self-management in safety net and non-safety net centers? (2019) (0)
- Ovarian Function Suppression in Women with Breast Cancer (2016) (0)
- Study supports weekly nab-paclitaxel for MBC (2007) (0)
- Intraoperative RT matches external beam in offsetting recurrence: Comment (2010) (0)
- Sentinel Lymph Node Biopsy After Neoadjuvant Chemotherapy for Breast Cancer (2013) (0)
- New Insights into Male Breast Cancer (2014) (0)
- Trastuzumab in regimens raises cardiotoxicity fivefold: Commentary (2012) (0)
- Novel risk factors for osteonecrosis of the jaw in multiple myeloma: A RADAR report. (2012) (0)
- Commentary: Ethics of Clinical Trials in Low-Resource Settings Vinay Prasad et al Development of a Breast Cancer Treatment Program in Port-au-Prince, Haiti Vincent DeGennaro et al Tuberculosis Diagnosis Delaying Treatment of Cancer (2016) (0)
- RIBBON 2: Adding second-line bevacizumab improves PFS: Commentary (2010) (0)
- Preserving Ovarian Function in Young Women with Breast Cancer (2017) (0)
- Insights from a Negative Result (2008) (0)
- HRT doesn't worsen breast cancer risk following oophorectomy: Commentary (2011) (0)
- PO58 EFFICACY AND SAFETY OF FIRST-LINE EVEROLIMUS PLUS LETROZOLE IN ER+ HER2− METASTATIC BREAST CANCER: A MULTI-CENTER, OPEN-LABEL, PHASE 2 TRIAL BOLERO-4 (2013) (0)
- Can We Be Confident of HER2 Testing (2014) (0)
- ESMO 2016 Report — Breast Cancer (2016) (0)
- SUCCESS-A: Not So Much! (2021) (0)
- Neoadjuvant AI therapy is effective in shrinking tumors: Comment (2010) (0)
- A case study from the Lynn Sage Comprehensive Cancer Center. Primary sarcoma of the breast: a diagnostic dilemma (2005) (0)
- Top Stories of 2019 (2019) (0)
- Capecitabine: treatment options in metastatic breast cancer (2009) (0)
- Corrigendum: High-dose chemotherapy, autologous bone marrow or stem cell transplantation and post-transplant consolidation chemotherapy in patients with advanced breast cancer (Bone Marrow Transplantation (1997) 20 (721-729)) (1998) (0)
- ALTERNATIVE (EGF114299): A study of lapatinib, trastuzumab, and endocrine therapy in patients who received neo-/adjuvant trastuzumab (IV) and endocrine therapy. (2012) (0)
- Risk Factors for Breast Cancer Recurrence and Systemic Disease (2010) (0)
- Prognostic Role of a Gene Signature in Breast Cancer (2007) (0)
- Targeting Defective DNA Repair Pathways in Triple-Negative Breast Cancer (2011) (0)
- Weight Loss for Overweight Cancer Patients: Benefits Aplenty (2012) (0)
- The Manhattan Project of Breast Cancer (2012) (0)
- Efficacy of Baseline Circulating Tumor Cells (CTCs) and Circulating Tumor DNA (ctDNA) for Evaluation of Tumor Heterogeneity and Clinical Outcome in Advanced Breast Cancer (2022) (0)
- Abstract PS2-06: The detection and enumeration of circulating tumor cells (CTCs) and circulating endothelial cells (CECs) in metastatic breast cancer (2021) (0)
- Have the recently completed phase III trials significantly impacted adjuvant treatment choices for stage II breast carcinoma? (1999) (0)
- Randomized phase II trial of gemcitabine versus gemcitabine and imatinib mesylate in patients with previously treated metastatic breast cancer. (2013) (0)
- Neoadjuvant Carboplatin for Triple-Negative Breast Cancer (2014) (0)
- Anthracycline-Based Adjuvant Chemotherapy for Early-Stage Breast Cancer (2006) (0)
- Assay results often lead to change in breast Ca treatment plan: Commentary (2010) (0)
- Chemotherapy: How Much Is Enough? (2013) (0)
- Finding the “Sweet Spot” with Adjuvant Endocrine Therapy for Breast Cancer (2021) (0)
- Another Adjuvant Option for Ductal Carcinoma In Situ (2016) (0)
- Letrozole or Tamoxifen for Initial Adjuvant Therapy in Breast Cancer (2007) (0)
- Hematology and Oncology Care During the COVID-19 Pandemic (2020) (0)
- BPI20-017: Innovating Patient-Facing Care Pathways in Breast Cancer Using the 4R model, 4R = Right Information / Care / Patient / Time (2020) (0)
- Predicting Breast Cancer Recurrence After Primary Chemotherapy (2012) (0)
- Aromatase-Inhibitor–Induced Joint Complaints: An Underappreciated Problem? (2007) (0)
- Receptor status change at recurrence heralds poor survival: Commentary (2008) (0)
- Fulvestrant for Aromatase-Inhibitor–Resistant Breast Cancer (2007) (0)
- Abstract 1501: Exceptional response to anti HER-2 targeted therapy in patient with HER2/neu negative breast cancer with HER2/neu positive CTCs (2020) (0)
- ODAC backs yanking avastin indication in MBC: Commentary (2011) (0)
- ESMO 2019 Report — Breast Cancer (2019) (0)
- Abstract P1-05-06: Estrogen receptor 1 (ESR1) mutations in circulating tumor DNA (ctDNA): A guide to the management of advanced breast cancer (ABC) (2017) (0)
- Monitoring Patients with Early-Stage Breast Cancer: Time to Reassess? (2019) (0)
- Concordance of genomic alterations by next generation sequencing (NGS) in tumor tissue vs. cell-free DNA in advanced breast cancer. (2016) (0)
This paper list is powered by the following services:
What Schools Are Affiliated With William John Gradishar?
William John Gradishar is affiliated with the following schools:
